uuid stringlengths 4 8 | template_uuid stringclasses 40
values | question stringlengths 13 193 | answer stringlengths 29 2.2k | benchmark_query stringlengths 133 622 | execution_results stringlengths 2 1.14M | query_type stringclasses 2
values | sql_category stringclasses 26
values | bio_category stringclasses 14
values |
|---|---|---|---|---|---|---|---|---|
Q17.602 | Q17 | What gene does the drug Morphine Sulfate target? | The drug Morphine Sulfate targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%morphine sulfate%" OR LOWER(tradeNames_string) LIKE "%morphine sulfate%" OR LOWER(drugSynonyms_string) LIKE "%morphine sulfate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3650', 'drugName': 'Morphine Sulfate', 'tradeNames_string': 'Arymo er, Astramorph pf, Avinza, Depodur, Duramorph, Duramorph pf, Duromorph, Filnarine sr, Infumorph, Kadian, Moraxen, Morcap sr, Morphabond, Morphabond er, Morphgesic sr, Morphine sulfate, Morphine sulfate (autoinjector), Ms contin, Mst continus, Oramorph, Oramorph sr, Oramorph udv, Rhotard, Sevredol, Srm-rhotard, Zomorph', 'drugSynonyms_string': 'Arymo, Astramorph, Dolcontin, Kapanol, Morcap, Morphine sulfate, Morphine sulfate anhydrous, Morphine sulfate cii, Morphine sulfate hydrate, Morphine sulfate pentahydrate, Morphine sulfate,anhydrous, Morphine sulphate, Morphine sulphate anhydrous, Morphine sulphate pentahydrate, Morphini sulfas, Moscontin, NSC-11441', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Opioid Use Disorder (EFO_0010702), Drug Dependence (EFO_0003890), Neonatal Abstinence Syndrome (EFO_0005799), Chronic Pain (HP_0012532), Pain (EFO_0003843), Osteoarthritis, Knee (EFO_0004616), Myocardial Infarction (EFO_0000612), Pulmonary Arterial Hypertension (EFO_0001361), Sickle Cell Anemia (MONDO_0011382), Hallux Valgus (HP_0001822), Low Back Pain (HP_0003419), Obstructive Sleep Apnea (EFO_0003918), Idiopathic Pulmonary Fibrosis (EFO_0000768), Pruritus (HP_0000989), Opioid Dependence (EFO_0005611)', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.63 | Q17 | What gene does the drug Eritoran target? | The drug Eritoran is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: LY96 and TLR4 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%eritoran%" OR LOWER(tradeNames_string) LIKE "%eritoran%" OR LOWER(drugSynonyms_string) LIKE "%eritoran%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1063', 'drugName': 'Eritoran Tetrasodium', 'tradeNames_string': '', 'drugSynonyms_string': 'B-1287, B1287, E-5564, E5564, Eritoran sodium, Eritoran tetrasodium, Eritoran tetrasodium salt', 'linkedDiseasesDrug_string': 'Sepsis (HP_0100806), Leukemia (EFO_0000565)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR4 (ENSG00000136869), LY96 (ENSG00000154589)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_600', 'drugName': 'Eritoran', 'tradeNames_string': '', 'drugSynonyms_string': 'E5564, Eritoran', 'linkedDiseasesDrug_string': 'Insulin Resistance (EFO_0002614), Sepsis (HP_0100806), Leukemia (EFO_0000565), Pneumonia (EFO_0003106), Covid-19 (MONDO_0100096), Influenza (EFO_0007328)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR4 (ENSG00000136869), LY96 (ENSG00000154589)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1309 | Q17 | What gene does the drug Acetazolamide Sodium target? | The drug Acetazolamide Sodium targets 4 genes: CA1, CA4, CA12 and CA2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%acetazolamide sodium%" OR LOWER(tradeNames_string) LIKE "%acetazolamide sodium%" OR LOWER(drugSynonyms_string) LIKE "%acetazolamide sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6141', 'drugName': 'Acetazolamide Sodium', 'tradeNames_string': 'Acetazolamide sodium, Diamox', 'drugSynonyms_string': 'Acetazolamide Sodium, Acetazolamide sodium, Acetazolamide sodium salt, Sodium acetazolamide, Vetamox', 'linkedDiseasesDrug_string': 'Edema (EFO_0009373), Angle-Closure Glaucoma (MONDO_0001744), Seizure (HP_0001250), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA4 (ENSG00000167434), CA1 (ENSG00000133742), CA12 (ENSG00000074410), CA2 (ENSG00000104267)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6140', 'drugName': 'Acetazolamide Sodium', 'tradeNames_string': 'Acetazolamide sodium, Diamox', 'drugSynonyms_string': 'Acetazolamide Sodium, Acetazolamide sodium, Acetazolamide sodium salt, Sodium acetazolamide, Vetamox', 'linkedDiseasesDrug_string': 'Edema (EFO_0009373), Angle-Closure Glaucoma (MONDO_0001744), Seizure (HP_0001250), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA4 (ENSG00000167434), CA1 (ENSG00000133742), CA12 (ENSG00000074410), CA2 (ENSG00000104267)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6143', 'drugName': 'Acetazolamide Sodium', 'tradeNames_string': 'Acetazolamide sodium, Diamox', 'drugSynonyms_string': 'Acetazolamide Sodium, Acetazolamide sodium, Acetazolamide sodium salt, Sodium acetazolamide, Vetamox', 'linkedDiseasesDrug_string': 'Edema (EFO_0009373), Angle-Closure Glaucoma (MONDO_0001744), Seizure (HP_0001250), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA4 (ENSG00000167434), CA1 (ENSG00000133742), CA12 (ENSG00000074410), CA2 (ENSG00000104267)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_6142', 'drugName': 'Acetazolamide Sodium', 'tradeNames_string': 'Acetazolamide sodium, Diamox', 'drugSynonyms_string': 'Acetazolamide Sodium, Acetazolamide sodium, Acetazolamide sodium salt, Sodium acetazolamide, Vetamox', 'linkedDiseasesDrug_string': 'Edema (EFO_0009373), Angle-Closure Glaucoma (MONDO_0001744), Seizure (HP_0001250), Glaucoma (MONDO_0005041)', 'yearOfFirstApproval': 1990, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA4 (ENSG00000167434), CA1 (ENSG00000133742), CA12 (ENSG00000074410), CA2 (ENSG00000104267)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.879 | Q17 | What gene does the drug Naratriptan target? | The drug Naratriptan targets 2 genes: HTR1B and HTR1D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naratriptan%" OR LOWER(tradeNames_string) LIKE "%naratriptan%" OR LOWER(drugSynonyms_string) LIKE "%naratriptan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4634', 'drugName': 'Naratriptan', 'tradeNames_string': 'Amerge, Naratriptan', 'drugSynonyms_string': 'Amerge, Naratriptan', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4633', 'drugName': 'Naratriptan', 'tradeNames_string': 'Amerge, Naratriptan', 'drugSynonyms_string': 'Amerge, Naratriptan', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5846', 'drugName': 'Naratriptan Hydrochloride', 'tradeNames_string': 'Amerge, Naramig, Naratriptan', 'drugSynonyms_string': 'GR 85548A, GR-85548A, Naratriptan hcl, Naratriptan hydrochloride', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5845', 'drugName': 'Naratriptan Hydrochloride', 'tradeNames_string': 'Amerge, Naramig, Naratriptan', 'drugSynonyms_string': 'GR 85548A, GR-85548A, Naratriptan hcl, Naratriptan hydrochloride', 'linkedDiseasesDrug_string': 'Migraine Disorder (MONDO_0005277), Headache (HP_0002315)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1491 | Q17 | What gene does the drug Methyldopa target? | The drug Methyldopa targets 3 genes: ADRA2A, ADRA2C and ADRA2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methyldopa%" OR LOWER(tradeNames_string) LIKE "%methyldopa%" OR LOWER(drugSynonyms_string) LIKE "%methyldopa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6296', 'drugName': 'Methyldopa', 'tradeNames_string': 'Aldomet, Dopamet, Lederdopa, Medomet, Metalpha 250, Metalpha 500, Methyldopa', 'drugSynonyms_string': '(-)-.alpha.-methyldopa, (s)-(-)-.alpha.-methyldopa, .alpha.-methyl-l-dopa, Alpha-methyldopa, Anhydrous methyldopa, BAYER-1440L, J9.247I, L-.alpha.-methyldopa, MK-351, Methyldopa, Methyldopa (levorotatory), Methyldopa anhydrous, Methyldopa hydrate, Methyldopa sesquihydrate, Methyldopa, anhydrous, NSC-169916, NSC-760080', 'linkedDiseasesDrug_string': 'Preeclampsia (EFO_0000668), Hypertension (EFO_0000537), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5960', 'drugName': 'Methyldopate Hydrochloride', 'tradeNames_string': 'Aldomet, Methyldopate hydrochloride', 'drugSynonyms_string': 'Methyldopa l-form ethyl ester hydrochloride, Methyldopate hcl, Methyldopate hydrochloride, NSC-760088', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_6307', 'drugName': 'Methyldopate', 'tradeNames_string': '', 'drugSynonyms_string': 'Methyldopate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1880 | Q17 | What gene does the drug Cerivastatin Sodium target? | The drug Cerivastatin Sodium targets the gene HMGCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cerivastatin sodium%" OR LOWER(tradeNames_string) LIKE "%cerivastatin sodium%" OR LOWER(drugSynonyms_string) LIKE "%cerivastatin sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3117', 'drugName': 'Cerivastatin Sodium', 'tradeNames_string': 'Baycol', 'drugSynonyms_string': 'BAY W 6228, BAY-W-6228, Cerivastatin sodium, Cerivastatin sodium salt', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HMGCR (ENSG00000113161)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.282 | Q17 | What gene does the drug Methaqualone Hydrochloride target? | The drug Methaqualone Hydrochloride targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methaqualone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%methaqualone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%methaqualone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2025', 'drugName': 'Methaqualone Hydrochloride', 'tradeNames_string': 'Optimil, Parest', 'drugSynonyms_string': 'Methaqualone hcl, Methaqualone hydrochloride, NSC-75892', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.37 | Q17 | What gene does the drug Amg-557 target? | The drug Amg-557 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene ICOSLG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amg-557%" OR LOWER(tradeNames_string) LIKE "%amg-557%" OR LOWER(drugSynonyms_string) LIKE "%amg-557%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1964', 'drugName': 'Amg-557', 'tradeNames_string': '', 'drugSynonyms_string': 'AMG-557, Amg-557, MEDI-5872, Medi 5872, Prezalumab', 'linkedDiseasesDrug_string': 'Sjogren Syndrome (EFO_0000699), Cutaneous Lupus Erythematosus (EFO_0003834), Systemic Lupus Erythematosus (MONDO_0007915), Psoriasis (EFO_0000676)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'ICOSLG (ENSG00000160223)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1517 | Q17 | What gene does the drug Benztropine Mesylate target? | The drug Benztropine Mesylate targets the gene CHRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%benztropine mesylate%" OR LOWER(tradeNames_string) LIKE "%benztropine mesylate%" OR LOWER(drugSynonyms_string) LIKE "%benztropine mesylate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_321', 'drugName': 'Benztropine Mesylate', 'tradeNames_string': 'Benztropine mesylate, Cogentin', 'drugSynonyms_string': 'Benzatropine mesilate, Benztropine mesilate, Benztropine mesylate, Benztropine methanesulfonate, NSC-169913', 'linkedDiseasesDrug_string': 'Back Pain (HP_0003418), Peripheral Nervous System Disease (EFO_0009387), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.669 | Q17 | What gene does the drug Cilastatin target? | The drug Cilastatin targets the gene DPEP1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cilastatin%" OR LOWER(tradeNames_string) LIKE "%cilastatin%" OR LOWER(drugSynonyms_string) LIKE "%cilastatin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1365', 'drugName': 'Cilastatin', 'tradeNames_string': '', 'drugSynonyms_string': 'Cilastatin, Primaxin', 'linkedDiseasesDrug_string': 'Bacterial Pneumonia (EFO_1001272), Infection (EFO_0000544), Sepsis (HP_0100806), Pneumonia (EFO_0003106), Ventilator-Associated Pneumonia (EFO_1001865), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Osteomyelitis (EFO_0003102), Urinary Tract Infection (EFO_0003103), Endocarditis (EFO_0000465), Pyelonephritis (EFO_1001141), Bacterial Disease (EFO_0000771)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DPEP1 (ENSG00000015413)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_185', 'drugName': 'Cilastatin Sodium', 'tradeNames_string': '', 'drugSynonyms_string': 'Cilastatin sodium, Cilastatin sodium salt, MK-791', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Sepsis (HP_0100806), Pneumonia (EFO_0003106), Urinary Tract Infection (EFO_0003103), Endocarditis (EFO_0000465)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DPEP1 (ENSG00000015413)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1829 | Q17 | What gene does the drug Pyrovalerone Hydrochloride target? | The drug Pyrovalerone Hydrochloride targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pyrovalerone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%pyrovalerone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%pyrovalerone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_471', 'drugName': 'Pyrovalerone Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'Centroton, F 1983, F-1983, Pyrovalerone hcl, Pyrovalerone hydrochloride, SP-1059, Thymergix', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1446 | Q17 | What gene does the drug Loperamide target? | The drug Loperamide targets the gene OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%loperamide%" OR LOWER(tradeNames_string) LIKE "%loperamide%" OR LOWER(drugSynonyms_string) LIKE "%loperamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3319', 'drugName': 'Loperamide', 'tradeNames_string': '', 'drugSynonyms_string': 'Imodium, Loperamide', 'linkedDiseasesDrug_string': 'Fecal Incontinence (EFO_0009523), Cancer (MONDO_0004992), Eczema (HP_0000964), Diarrhea (HP_0002014), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Intestinal Obstruction (MONDO_0004565), Non-Small Cell Lung Carcinoma (EFO_0003060), Pain (EFO_0003843), Clostridium Difficile Infection (EFO_0009130), Reproductive System Disease (EFO_0000512), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6052', 'drugName': 'Loperamide Hydrochloride', 'tradeNames_string': 'Arret, Diah-limit, Diaquitte, Diareze, Diarrhoea relief, Diasorb, Diocalm, Diocaps, Dioraleze, Entrocalm, Gppe pack, Imodium, Imodium Advanced, Imodium a-d, Imodium a-d ez chews, Imodium classic, Imodium ibs relief, Imodium instant melts, Imodium instants, Imodium liquicaps, Lodiar, Loperagen, Loperamide hydrochloride, Norimode, Normaloe', 'drugSynonyms_string': 'Loperamide hcl, Loperamide hydrochloride, Loperamidi hydrochloridum, NSC-696356, R 18,553, R-18553', 'linkedDiseasesDrug_string': 'Diarrhea (HP_0002014)', 'yearOfFirstApproval': 1976, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.986 | Q17 | What gene does the drug Quinethazone target? | The drug Quinethazone targets the gene SLC12A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%quinethazone%" OR LOWER(tradeNames_string) LIKE "%quinethazone%" OR LOWER(drugSynonyms_string) LIKE "%quinethazone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5602', 'drugName': 'Quinethazone', 'tradeNames_string': 'Hydromox', 'drugSynonyms_string': 'Chinethazone, NSC-759904, Quinethazone', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 1963, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A3 (ENSG00000070915)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1572 | Q17 | What gene does the drug Ss1(Dsfv)-Pe38 target? | The drug Ss1(Dsfv)-Pe38 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene MSLN. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ss1(dsfv)-pe38%" OR LOWER(tradeNames_string) LIKE "%ss1(dsfv)-pe38%" OR LOWER(drugSynonyms_string) LIKE "%ss1(dsfv)-pe38%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6058', 'drugName': 'Ss1(Dsfv)-Pe38', 'tradeNames_string': '', 'drugSynonyms_string': 'SS1(DSFV)-PE38, Ss1(dsfv)-pe38', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Lung Cancer (MONDO_0008903), Neoplasm (EFO_0000616), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Cervical Cancer (MONDO_0002974)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'MSLN (ENSG00000102854)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.745 | Q17 | What gene does the drug Bromodiphenhydramine target? | The drug Bromodiphenhydramine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bromodiphenhydramine%" OR LOWER(tradeNames_string) LIKE "%bromodiphenhydramine%" OR LOWER(drugSynonyms_string) LIKE "%bromodiphenhydramine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4863', 'drugName': 'Bromodiphenhydramine', 'tradeNames_string': '', 'drugSynonyms_string': '4-bromodiphen hydramine, Bromazine, Bromodiphenhydramine, Deserol, Histabromamine, Neo-benadryl', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271)', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1015', 'drugName': 'Bromodiphenhydramine Hydrochloride', 'tradeNames_string': 'Ambodryl', 'drugSynonyms_string': 'Bromazine, Bromodiphenhydramine hcl, Bromodiphenhydramine hydrochloride, NSC-36113', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.194 | Q17 | What gene does the drug Luspatercept target? | The drug Luspatercept targets 3 genes: TGFB2, TGFB3 and TGFB1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%luspatercept%" OR LOWER(tradeNames_string) LIKE "%luspatercept%" OR LOWER(drugSynonyms_string) LIKE "%luspatercept%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6093', 'drugName': 'Luspatercept', 'tradeNames_string': 'Reblozyl', 'drugSynonyms_string': 'ACE-536, Luspatercept, Luspatercept aamt, Luspatercept-aamt', 'linkedDiseasesDrug_string': 'Beta-Thalassemia (Orphanet_848), Thalassemia (EFO_1001996), Anemia (Phenotype) (EFO_0004272), Myeloproliferative Disorder (EFO_0004251), Anemia (MONDO_0002280), Aplastic Anemia (HP_0001915), Myelodysplastic Syndrome (EFO_0000198)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TGFB1 (ENSG00000105329), TGFB2 (ENSG00000092969), TGFB3 (ENSG00000119699)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.927 | Q17 | What gene does the drug Carvedilol Phosphate target? | The drug Carvedilol Phosphate targets 6 genes: ADRB2, ADRB1, ADRA1A, ADRA1D, ADRA1B and ADRB3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%carvedilol phosphate%" OR LOWER(tradeNames_string) LIKE "%carvedilol phosphate%" OR LOWER(drugSynonyms_string) LIKE "%carvedilol phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_906', 'drugName': 'Carvedilol Phosphate', 'tradeNames_string': 'Coreg cr', 'drugSynonyms_string': 'Carvedilol phosphate, Carvedilol phosphate hemihydrate, Carvedilol phosphate hydrate, SK&F-105517-D, SKF 105517D, SKF-105517D', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 6}, {'UUID': 'DrugGeneTargets_v2_907', 'drugName': 'Carvedilol Phosphate', 'tradeNames_string': 'Coreg cr', 'drugSynonyms_string': 'Carvedilol phosphate, Carvedilol phosphate hemihydrate, Carvedilol phosphate hydrate, SK&F-105517-D, SKF 105517D, SKF-105517D', 'linkedDiseasesDrug_string': 'Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Myocardial Infarction (EFO_0000612)', 'yearOfFirstApproval': 2006, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), ADRB3 (ENSG00000188778), ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.462 | Q17 | What gene does the drug Cocaine target? | The drug Cocaine targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cocaine%" OR LOWER(tradeNames_string) LIKE "%cocaine%" OR LOWER(drugSynonyms_string) LIKE "%cocaine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3300', 'drugName': 'Apomorphine Hydrochloride', 'tradeNames_string': 'Apo-go, Apo-go pen, Apo-go pfs, Apokyn, Apomorph hcl, Britaject, Bromophin, Dacepton, Diagesil, Diamorph hcl, Diamorph roche, Diamorph,cocaine,chlorpromazine, Diaphine, Euphorin, Kynmobi, Uprima', 'drugSynonyms_string': 'Apokinon, Apomine, Apomorphine HCl, Apomorphine hcl, Apomorphine hydrochloride, Apomorphine hydrochloride hemihydrate, Apomorphine hydrochloride hydrate, Apomorphinum muriaticum, Diamorphine hydrochloride , Ixense, Kw-6500, NSC-11442, NSC-755875, Taluvian', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Osteoporosis (EFO_0003882), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DRD2 (ENSG00000149295), DRD3 (ENSG00000151577), DRD4 (ENSG00000069696)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_5902', 'drugName': 'Cocaine', 'tradeNames_string': '', 'drugSynonyms_string': '(r)-(-)-cocaine, Benzoylmethylecgonine, Cocaine, Cocainum, IDS-NC-004, Neurocaine, RX-0041, RX0041', 'linkedDiseasesDrug_string': 'Allergic Disease (MONDO_0005271), Substance Withdrawal Syndrome (EFO_0005800), Opioid Dependence (EFO_0005611), Cocaine Dependence (EFO_0002610)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_3417', 'drugName': 'Cocaine Hydrochloride', 'tradeNames_string': 'Goprelto, Numbrino', 'drugSynonyms_string': 'Cocaine hcl, Cocaine hydrochloride, Cocaine hydrochloride cii, Cocaine muriate, Cocainum muriaticum, MCV 4526, NIH 8211, NSC-25263, RX-0041-002', 'linkedDiseasesDrug_string': 'Cocaine Dependence (EFO_0002610)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.682 | Q17 | What gene does the drug Blinatumomab target? | The drug Blinatumomab targets 4 genes: CD3E, CD3G, CD19 and CD3D. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%blinatumomab%" OR LOWER(tradeNames_string) LIKE "%blinatumomab%" OR LOWER(drugSynonyms_string) LIKE "%blinatumomab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4607', 'drugName': 'Blinatumomab', 'tradeNames_string': '', 'drugSynonyms_string': 'Blinatumomab, MEDI-538, MT-103', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoma (EFO_0000574), Acute Lymphoblastic Leukemia (EFO_0000220), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), CD19 (ENSG00000177455)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_4608', 'drugName': 'Blinatumomab', 'tradeNames_string': '', 'drugSynonyms_string': 'Blinatumomab, MEDI-538, MT-103', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), T-Cell Acute Lymphoblastic Leukemia (EFO_0000209), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), B-Cell Acute Lymphoblastic Leukemia (EFO_0000094), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoma (EFO_0000574), Acute Lymphoblastic Leukemia (EFO_0000220), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 2014, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CD3E (ENSG00000198851), CD3G (ENSG00000160654), CD3D (ENSG00000167286), CD19 (ENSG00000177455)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.767 | Q17 | What gene does the drug Pelabresib target? | The drug Pelabresib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: BRD3, BRDT, BRD2 and BRD4 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pelabresib%" OR LOWER(tradeNames_string) LIKE "%pelabresib%" OR LOWER(drugSynonyms_string) LIKE "%pelabresib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_866', 'drugName': 'Pelabresib', 'tradeNames_string': '', 'drugSynonyms_string': 'CPI-0610, CPI-232, CPI-267232, Cpi 0610, Cpi-0610, Cpi-0610 anhydrous, Pelabresib, Pelabresib anhydrous, Pelabresib monohydrate', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Myelofibrosis (MONDO_0044903), Lymphoma (EFO_0000574), Tumour Of Cranial And Spinal Nerves (EFO_0002431)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'BRD2 (ENSG00000204256), BRD4 (ENSG00000141867), BRDT (ENSG00000137948), BRD3 (ENSG00000169925)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1809 | Q17 | What gene does the drug Estradiol target? | The drug Estradiol targets the gene ESR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%estradiol%" OR LOWER(tradeNames_string) LIKE "%estradiol%" OR LOWER(drugSynonyms_string) LIKE "%estradiol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4393', 'drugName': 'Estradiol Valerate', 'tradeNames_string': 'Climaval, Delestrogen, Estradiol valerate, Femtab, Progynon depot, Progynon-depot-10, Progynova', 'drugSynonyms_string': '.beta.-estradiol 17-valerate, Estradiol 17-valerate, Estradiol Valerate, Estradiol valerate, NSC-17590, Oestradiol valerate', 'linkedDiseasesDrug_string': 'Hypogonadism (MONDO_0002146), Polycystic Ovary Syndrome (EFO_0000660), Menorrhagia (HP_0000132), Atrophic Vaginitis (EFO_1001271), Menopause (EFO_0003922), Infertility (EFO_0000545), Premature Ovarian Insufficiency (HP_0008209), Dysmenorrhea (HP_0100607), Atrophy (EFO_1000096), Metrorrhagia (HP_0100608), Primary Ovarian Insufficiency (EFO_0004266)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_223', 'drugName': 'Estriol', 'tradeNames_string': 'Gynest, Ortho-gynest, Ovestin, Theelol', 'drugSynonyms_string': '16.ALPHA.-HYDROXYESTRADIOL, 16.alpha.,17.beta.-estriol, Aacifemine, Colpogyn, Estriol, Estriol acetate benzoate, Estriol propionate, Estriol succinate, Incurin, NSC-12169, Oestriol, Trihydroxyestrin', 'linkedDiseasesDrug_string': 'Secondary Progressive Multiple Sclerosis (EFO_0008522), Atrophic Vaginitis (EFO_1001271), Menopause (EFO_0003922), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Pregnancy (EFO_0002950), Primary Progressive Multiple Sclerosis (EFO_0008520)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR2 (ENSG00000140009), ESR1 (ENSG00000091831)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5776', 'drugName': 'Ethinyl Estradiol', 'tradeNames_string': 'Estinyl, Etinestryl, Feminone, Follicoral, Lynoral', 'drugSynonyms_string': '17-ethinylestradiol, 17alpha-ethinylestradiol, Enovid, Enovid-E, Ethinyl Estradiol, Ethinyl estradiol, Ethinylestradiol, Ethinylestradiolum, Ethinyloestradiol, Ethynylestradiol, Ginestrene, NSC-10973, Norinyl, Ovulen, Ovulen-21, Ovulen-28', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Chronic Lymphocytic Leukemia (EFO_0000095), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Metrorrhagia (HP_0100608), Hyperandrogenism (EFO_0009006), Endometrial Cancer (MONDO_0011962), Pregnancy (EFO_0002950), Anorexia Nervosa (MONDO_0005351), Hepatitis C Virus Infection (EFO_0003047), Osteoporosis (EFO_0003882), Osteopenia (HP_0000938), Polycystic Ovary Syndrome (EFO_0000660), Breast Cancer (MONDO_0007254), Chronic Hepatitis B Virus Infection (EFO_0004239), Non-Alcoholic Steatohepatitis (EFO_1001249), Neural Tube Defect (MONDO_0018075), Amenorrhea (EFO_0010269), Acne (EFO_0003894), Turner Syndrome (MONDO_0019499), Binge Eating (EFO_0005924), Hiv-1 Infection (EFO_0000180), Chronic Hepatitis C Virus Infection (EFO_0004220), Depressive Disorder (MONDO_0002050), Premenstrual Tension (MONDO_0004169), Female Infertility (EFO_0008560), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Cystic Fibrosis (MONDO_0009061), Bulimia Nervosa (EFO_0005204), Type 2 Diabetes Mellitus (MONDO_0005148), Hidradenitis Suppurativa (EFO_1000710)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3573', 'drugName': 'Estrone', 'tradeNames_string': 'Estrogenic substance, Estrone, Natural estrogenic substance-estrone, Oestrone, Theelin', 'drugSynonyms_string': '1,3,5-estratrien-3-ol-17-one, Estradiol metabolite e1, Estrone, Follicular hormone, Follicular-hormone, Folliculin, Folliculinum, Ketohydroxyestrin, NSC-9699, Oestrone, Theelin, Thelykinin, Tokokin, WAY 164397', 'linkedDiseasesDrug_string': 'Obesity (EFO_0001073), Premenstrual Tension (MONDO_0004169)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6277', 'drugName': 'Estradiol', 'tradeNames_string': 'Adgyn estro, Alora, Aquagen, Bedol, Climara, Climara Pro, Dermestril 100, Dermestril 25, Dermestril 50, Dermestril septem 25, Dermestril septem 50, Dermestril septem 75, Divigel, E-Cypionate, Elestrim, Elestrin, Elleste solo, Elleste solo mx 40, Elleste solo mx 80, Esclim, Estrace, Estraderm, Estraderm mx 100, Estraderm mx 25, Estraderm mx 50, Estraderm mx 75, Estraderm tts 100, Estraderm tts 25, Estraderm tts 50, Estradiol, Estrasorb, Estring, Estrogel, Evamist, Evorel 100, Evorel 25, Evorel 50, Evorel 75, Fematrix 40, Fematrix 80, Fempatch, Femseven 100, Femseven 50, Femseven 75, Gvnodiol, Gynodiol, Gynogen, Imvexxy, Innofem, Menorest 37.5, Menorest 50, Menorest 75, Menoring 50, Menostar, Minivelle, Oestradiol, Progynova ts, Sandrena, Vagifem, Vagifem 18, Vagifem 8, Vivelle, Vivelle-dot, Zumenon', 'drugSynonyms_string': '17-.beta.-oestradiol, 17-beta-oestradiol, 17.beta.-estradiol, 17beta-estradiol, Agofollin, Alfatradiol, Depo-Estradiol, Destradiol, Dihydrotheelin, Dihydroxyestrin, Estradiol, Estradiol 17-beta, Estradiol anhydrous, Estradiol hemihydrate, Estradiol valerate metabolite e2, Estrasorb, Gynergon, Gynoestryl, NSC-20293, NSC-9895, Oestradiol, WC-3011, WC3011', 'linkedDiseasesDrug_string': 'Alzheimer Disease (MONDO_0004975), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Covid-19 (MONDO_0100096), Uterine Fibroid (EFO_0000731), Migraine Disorder (MONDO_0005277), Dysmenorrhea (HP_0100607), Obesity (EFO_0001073), Dry Eye Syndrome (EFO_1000906), Atherosclerosis (EFO_0003914), Aging (GO_0007568), Anorexia Nervosa (MONDO_0005351), Hot Flashes (HP_0031217), Prostate Carcinoma (EFO_0001663), Breast Carcinoma (EFO_0000305), Myocardial Ischemia (EFO_1001375), Post-Traumatic Stress Disorder (EFO_0001358), Osteoporosis (EFO_0003882), Breast Neoplasm (EFO_0003869), Prostate Cancer (MONDO_0008315), Cerebral Arterial Disease (EFO_1000859), Breast Cancer (MONDO_0007254), Polycystic Ovary Syndrome (EFO_0000660), Osteopenia (HP_0000938), Postpartum Depression (EFO_0007453), Premature Ovarian Insufficiency (HP_0008209), Schizoaffective Disorder (EFO_0005411), Non-Alcoholic Steatohepatitis (EFO_1001249), Endometriosis (EFO_0001065), Amenorrhea (EFO_0010269), Sexual Dysfunction (EFO_0004714), Postmenopausal Atrophic Vaginitis (MONDO_0001410), Hypogonadism (MONDO_0002146), Turner Syndrome (MONDO_0019499), Menopause (EFO_0003922), Infertility (EFO_0000545), Urinary Tract Infection (EFO_0003103), Carcinoid Tumor (EFO_0004243), Hiv-1 Infection (EFO_0000180), Depressive Disorder (MONDO_0002050), Hiv Infection (EFO_0000764), Type 2 Diabetes Mellitus (MONDO_0005148), Atrophic Vaginitis (EFO_1001271), Blood Coagulation Disease (EFO_0009314), Atrophy (EFO_1000096), Bulimia Nervosa (EFO_0005204), Type 1 Diabetes Mellitus (MONDO_0005147), Dyspareunia (HP_0030016), Schizophrenia (MONDO_0005090), Hereditary Breast And Ovarian Cancer Syndrome (Orphanet_145)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5051', 'drugName': 'Polyestradiol Phosphate', 'tradeNames_string': 'Estradurin, Polyest phos', 'drugSynonyms_string': 'Estradiol phosphate polymer, LEO 114, LEO-114, Polyestradiol phos phosphate, Polyestradiol phosphate', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3260', 'drugName': 'Estradiol Acetate', 'tradeNames_string': 'Femring, Femtrace', 'drugSynonyms_string': 'E3A, ESTRADIOL-3-ACETATE, Estradiol 3-acetate, Estradiol acetate', 'linkedDiseasesDrug_string': 'Atrophy (EFO_1000096), Menopause (EFO_0003922)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_612', 'drugName': 'Estradiol Cypionate', 'tradeNames_string': 'Depo, Depo-estradiol, Estradiol cypionate', 'drugSynonyms_string': 'Estradiol 17.beta.-cyclopentanepropanoate, Estradiol cipionate, Estradiol cypionate, NSC-3354', 'linkedDiseasesDrug_string': 'Postmenopausal Atrophic Vaginitis (MONDO_0001410), Hypogonadism (MONDO_0002146), Osteoporosis (EFO_0003882), Postmenopausal Osteoporosis (EFO_0003854), Breast Cancer (MONDO_0007254), Dyspareunia (HP_0030016), Menopause (EFO_0003922), Covid-19 (MONDO_0100096), Atrophy (EFO_1000096), Primary Ovarian Insufficiency (EFO_0004266)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ESR1 (ENSG00000091831)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1603 | Q17 | What gene does the drug Kbp5209 target? | The drug Kbp5209 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 4 genes: ERBB3, ERBB2, ERBB4 and EGFR | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%kbp5209%" OR LOWER(tradeNames_string) LIKE "%kbp5209%" OR LOWER(drugSynonyms_string) LIKE "%kbp5209%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5199', 'drugName': 'Kbp5209', 'tradeNames_string': '', 'drugSynonyms_string': 'KBP5209, Kbp-5209, Kbp5209', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB2 (ENSG00000141736), EGFR (ENSG00000146648), ERBB4 (ENSG00000178568), ERBB3 (ENSG00000065361)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.735 | Q17 | What gene does the drug Methocarbamol target? | The drug Methocarbamol targets the gene CA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methocarbamol%" OR LOWER(tradeNames_string) LIKE "%methocarbamol%" OR LOWER(drugSynonyms_string) LIKE "%methocarbamol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5220', 'drugName': 'Methocarbamol', 'tradeNames_string': 'Delaxin, Forbaxin, Methocarbamol, Miolaxin, Neuraxin, Robaxin, Robaxin-750', 'drugSynonyms_string': 'Methocarbamol, NSC-170960', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 1957, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CA1 (ENSG00000133742)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.418 | Q17 | What gene does the drug Naloxone Hydrochloride target? | The drug Naloxone Hydrochloride targets 3 genes: OPRK1, OPRM1 and OPRD1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%naloxone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%naloxone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%naloxone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3927', 'drugName': 'Naloxone Hydrochloride', 'tradeNames_string': 'Evzio, Evzio (autoinjector), Kloxxado, Nalone, Naloxone, Naloxone hydrochloride, Naloxone hydrochloride (autoinjector), Narcan, Narcan neonatal, Narconil, Prenoxad, Zimhi', 'drugSynonyms_string': 'Anhydrous naloxone hydrochloride, EN-15304, NIH 7890, NSC-757109, Naloxone hcl, Naloxone hydrochloride, Naloxone hydrochloride anhydrous, Naloxoni hydrochloridum anhydrous, Narcanti', 'linkedDiseasesDrug_string': 'Unipolar Depression (EFO_0003761), Intestinal Obstruction (MONDO_0004565), Septic Shock (EFO_0006834), Pain (EFO_0003843), Constipation (HP_0002019), Opioid Dependence (EFO_0005611), Gambling Behaviour (EFO_0004699)', 'yearOfFirstApproval': 1971, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'OPRK1 (ENSG00000082556), OPRD1 (ENSG00000116329), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1107 | Q17 | What gene does the drug Ethacrynic Acid target? | The drug Ethacrynic Acid targets the gene SLC12A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ethacrynic acid%" OR LOWER(tradeNames_string) LIKE "%ethacrynic acid%" OR LOWER(drugSynonyms_string) LIKE "%ethacrynic acid%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3791', 'drugName': 'Ethacrynic Acid', 'tradeNames_string': 'Edecrin, Ethacrynic acid, Hydromedin, Reomax', 'drugSynonyms_string': 'Etacrynic acid, Ethacrynate, Ethacrynic acid, MK-595, NSC-624008, NSC-85791', 'linkedDiseasesDrug_string': 'Nephrotic Syndrome (EFO_0004255), Congestive Heart Failure (EFO_0000373), Urinary Bladder Cancer (MONDO_0001187), Cardiovascular Disease (EFO_0000319), Urinary System Disease (EFO_0009690), Glaucoma (MONDO_0005041), Pulmonary Edema (EFO_1001134), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A1 (ENSG00000074803)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3044', 'drugName': 'Ethacrynate Sodium', 'tradeNames_string': 'Edecrin, Ethacrynate sodium', 'drugSynonyms_string': 'Etacrynate sodium, Ethacrynate sodium, Ethacrynic acid sodium salt, Sodium etacrynate, Sodium ethacrynate', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC12A1 (ENSG00000074803)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.832 | Q17 | What gene does the drug Tapentadol Hydrochloride target? | The drug Tapentadol Hydrochloride targets 2 genes: SLC6A2 and OPRM1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tapentadol hydrochloride%" OR LOWER(tradeNames_string) LIKE "%tapentadol hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%tapentadol hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6372', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_string': 'Nucynta, Nucynta er, Palexia', 'drugSynonyms_string': 'BN-200 HYDROCHLORIDE, CG-5503 HYDROCHLORIDE, CG5503 HYDROCHLORIDE, Tapentadol hcl, Tapentadol hydrochloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Neuropathic Pain (EFO_0005762)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6373', 'drugName': 'Tapentadol Hydrochloride', 'tradeNames_string': 'Nucynta, Nucynta er, Palexia', 'drugSynonyms_string': 'BN-200 HYDROCHLORIDE, CG-5503 HYDROCHLORIDE, CG5503 HYDROCHLORIDE, Tapentadol hcl, Tapentadol hydrochloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Chronic Pain (HP_0012532), Low Back Pain (HP_0003419), Neuropathic Pain (EFO_0005762)', 'yearOfFirstApproval': 2008, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), OPRM1 (ENSG00000112038)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1498 | Q17 | What gene does the drug Prexigebersen target? | The drug Prexigebersen is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene GRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%prexigebersen%" OR LOWER(tradeNames_string) LIKE "%prexigebersen%" OR LOWER(drugSynonyms_string) LIKE "%prexigebersen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6066', 'drugName': 'Prexigebersen', 'tradeNames_string': '', 'drugSynonyms_string': 'BP-100-1.01/L-Grb2, BP-1001, L-grb-2 antisense, Prexigebersen', 'linkedDiseasesDrug_string': 'Acute Myeloid Leukemia (EFO_0000222)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'GRB2 (ENSG00000177885)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.623 | Q17 | What gene does the drug Esomeprazole Sodium target? | The drug Esomeprazole Sodium targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%esomeprazole sodium%" OR LOWER(tradeNames_string) LIKE "%esomeprazole sodium%" OR LOWER(drugSynonyms_string) LIKE "%esomeprazole sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3760', 'drugName': 'Esomeprazole Sodium', 'tradeNames_string': 'Esomeprazole sodium, Nexium, Nexium iv', 'drugSynonyms_string': 'Esomeprazole (as sodium), Esomeprazole sodium, H199/18 SODIUM', 'linkedDiseasesDrug_string': 'Duodenal Ulcer (EFO_0004607), Gastroesophageal Reflux Disease (EFO_0003948), Peptic Ulcer Disease (MONDO_0004247)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.117 | Q17 | What gene does the drug Encainide target? | The drug Encainide targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%encainide%" OR LOWER(tradeNames_string) LIKE "%encainide%" OR LOWER(drugSynonyms_string) LIKE "%encainide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4728', 'drugName': 'Encainide', 'tradeNames_string': '', 'drugSynonyms_string': 'Encainide', 'linkedDiseasesDrug_string': 'Cardiac Arrhythmia (EFO_0004269)', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_6219', 'drugName': 'Encainide Hydrochloride', 'tradeNames_string': 'Enkaid', 'drugSynonyms_string': 'Encainide hcl, Encainide hydrochloride, MJ 9067-1, MJ-9067, MJ-9067-1', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.423 | Q17 | What gene does the drug Levocabastine target? | The drug Levocabastine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levocabastine%" OR LOWER(tradeNames_string) LIKE "%levocabastine%" OR LOWER(drugSynonyms_string) LIKE "%levocabastine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_396', 'drugName': 'Levocabastine', 'tradeNames_string': 'Livostin direct', 'drugSynonyms_string': 'Levocabastine, R-50547', 'linkedDiseasesDrug_string': 'Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Eye Allergy (EFO_0005751), Nasal Congestion (HP_0001742)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_674', 'drugName': 'Levocabastine Hydrochloride', 'tradeNames_string': 'Livostin', 'drugSynonyms_string': 'Levocabastine hcl, Levocabastine hydrochloride, R 50,547, R-50547', 'linkedDiseasesDrug_string': 'Rhinitis, Allergic, Perennial (EFO_1001417)', 'yearOfFirstApproval': 1993, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1911 | Q17 | What gene does the drug Lanreotide target? | The drug Lanreotide targets 2 genes: SSTR2 and SSTR5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lanreotide%" OR LOWER(tradeNames_string) LIKE "%lanreotide%" OR LOWER(drugSynonyms_string) LIKE "%lanreotide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2627', 'drugName': 'Lanreotide Acetate', 'tradeNames_string': 'Somatuline depot', 'drugSynonyms_string': 'BIM-23014C, Lanreotide acetate, Somatuline, Somatuline lp', 'linkedDiseasesDrug_string': 'Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Acromegaly (EFO_1001485), Carcinoid Syndrome (EFO_1000852)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2626', 'drugName': 'Lanreotide Acetate', 'tradeNames_string': 'Somatuline depot', 'drugSynonyms_string': 'BIM-23014C, Lanreotide acetate, Somatuline, Somatuline lp', 'linkedDiseasesDrug_string': 'Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Acromegaly (EFO_1001485), Carcinoid Syndrome (EFO_1000852)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_324', 'drugName': 'Lanreotide', 'tradeNames_string': 'Somatuline autogel, Somatuline la', 'drugSynonyms_string': 'Angiopeptin, Lanreotide', 'linkedDiseasesDrug_string': 'Pituitary Gland Adenoma (EFO_1000478), Carcinoid Heart Disease (EFO_1001769), Intestinal Disease (EFO_0009431), Rectal Carcinoma (MONDO_0044937), Hepatocellular Carcinoma (EFO_0000182), Diarrhea (HP_0002014), Graves Ophthalmopathy (EFO_1001466), Prostate Cancer (MONDO_0008315), Hyperglycemia (HP_0003074), Acromegaly (EFO_1001485), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Neuroendocrine Neoplasm (EFO_1001901), Intestinal Obstruction (MONDO_0004565), Carcinoid Tumor (EFO_0004243), Peptic Esophagitis (EFO_1001095), Endocrine Neoplasm (EFO_0003769), Dumping Syndrome (EFO_1001307), Merkel Cell Skin Cancer (EFO_1001471), Carcinoid Syndrome (EFO_1000852), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_323', 'drugName': 'Lanreotide', 'tradeNames_string': 'Somatuline autogel, Somatuline la', 'drugSynonyms_string': 'Angiopeptin, Lanreotide', 'linkedDiseasesDrug_string': 'Pituitary Gland Adenoma (EFO_1000478), Carcinoid Heart Disease (EFO_1001769), Intestinal Disease (EFO_0009431), Rectal Carcinoma (MONDO_0044937), Hepatocellular Carcinoma (EFO_0000182), Diarrhea (HP_0002014), Graves Ophthalmopathy (EFO_1001466), Prostate Cancer (MONDO_0008315), Hyperglycemia (HP_0003074), Acromegaly (EFO_1001485), Autosomal Dominant Polycystic Kidney Disease (EFO_1001496), Digestive System Neuroendocrine Neoplasm (MONDO_0024503), Neuroendocrine Neoplasm (EFO_1001901), Intestinal Obstruction (MONDO_0004565), Carcinoid Tumor (EFO_0004243), Peptic Esophagitis (EFO_1001095), Endocrine Neoplasm (EFO_0003769), Dumping Syndrome (EFO_1001307), Merkel Cell Skin Cancer (EFO_1001471), Carcinoid Syndrome (EFO_1000852), Neoplasm (EFO_0000616)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SSTR5 (ENSG00000162009), SSTR2 (ENSG00000180616)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.978 | Q17 | What gene does the drug Tipifarnib target? | The drug Tipifarnib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: FNTB and FNTA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tipifarnib%" OR LOWER(tradeNames_string) LIKE "%tipifarnib%" OR LOWER(drugSynonyms_string) LIKE "%tipifarnib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3546', 'drugName': 'Tipifarnib', 'tradeNames_string': '', 'drugSynonyms_string': 'NSC-702818, R-11577, R-115777, R115777, Tipifarnib, Zarnestra', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Primary Myelofibrosis (EFO_0002430), Medulloblastoma (EFO_0002939), T-Cell Large Granular Lymphocyte Leukemia (MONDO_0019469), Chronic Lymphocytic Leukemia (EFO_0000095), Essential Thrombocythemia (EFO_0000479), Oligodendroglioma (EFO_0000632), Urothelial Carcinoma (EFO_0008528), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Juvenile Myelomonocytic Leukemia (EFO_1000309), Breast Carcinoma (EFO_0000305), Breast Neoplasm (EFO_0003869), Gliosarcoma (EFO_1001465), Prostate Cancer (MONDO_0008315), Breast Cancer (MONDO_0007254), Acute Myelomonocytic Leukemia (EFO_0000223), Mantle Cell Lymphoma (EFO_1001469), Chronic Myelomonocytic Leukemia (EFO_1001779), Male Breast Carcinoma (EFO_0006861), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Acute Myeloid Leukemia (EFO_0000222), Head And Neck Squamous Cell Carcinoma (EFO_0000181), Cerebral Astrocytoma (MONDO_0021633), Inflammatory Breast Carcinoma (EFO_1000984), Pancreatic Carcinoma (EFO_0002618), Central Nervous System Neoplasm (EFO_1000158), Thyroid Cancer (MONDO_0002108), Malignant Tumor Of Neck (MONDO_0021310), Acute Erythroleukemia (EFO_0000218), Chronic Myeloproliferative Disorder (EFO_0002428), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Myeloblastic Leukemia With Maturation (EFO_0003028), Melanoma (EFO_0000756), Adult Acute Monocytic Leukemia (EFO_1001933), Primitive Neuroectodermal Tumor (EFO_0005235), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'FNTA (ENSG00000168522), FNTB (ENSG00000257365)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.611 | Q17 | What gene does the drug Safinamide target? | The drug Safinamide targets the gene MAOB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%safinamide%" OR LOWER(tradeNames_string) LIKE "%safinamide%" OR LOWER(drugSynonyms_string) LIKE "%safinamide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4183', 'drugName': 'Safinamide', 'tradeNames_string': 'Xadago', 'drugSynonyms_string': 'EMD 1195686, EMD-1195686, Safinamide', 'linkedDiseasesDrug_string': 'Kidney Disease (EFO_0003086), Liver Disease (EFO_0001421), Multiple System Atrophy (EFO_1001050), Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOB (ENSG00000069535)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1874', 'drugName': 'Safinamide Mesylate', 'tradeNames_string': 'Xadago', 'drugSynonyms_string': 'EMD 1195686, NW 1015, NW-1015, PNU 151774E, PNU-151774E, Safinamide mesilate, Safinamide mesylate, Safinamide methanesulfonate, Safinamide methansulfonate', 'linkedDiseasesDrug_string': 'Parkinson Disease (MONDO_0005180)', 'yearOfFirstApproval': 2017, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MAOB (ENSG00000069535)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1919 | Q17 | What gene does the drug Oxybutynin Chloride target? | The drug Oxybutynin Chloride targets 2 genes: CHRM2 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%oxybutynin chloride%" OR LOWER(tradeNames_string) LIKE "%oxybutynin chloride%" OR LOWER(drugSynonyms_string) LIKE "%oxybutynin chloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_871', 'drugName': 'Oxybutynin Chloride', 'tradeNames_string': 'Ditropan, Ditropan xl, Gelnique, Oxybutynin chloride', 'drugSynonyms_string': '5058, MJ 4309-1, MJ-4309-1, NSC-759108, Oxybutynin chloride, Oxybutynin hydrochloride, Pollakisu, Tropax', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Urinary Incontinence (HP_0000020), Prostate Carcinoma (EFO_0001663)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_872', 'drugName': 'Oxybutynin Chloride', 'tradeNames_string': 'Ditropan, Ditropan xl, Gelnique, Oxybutynin chloride', 'drugSynonyms_string': '5058, MJ 4309-1, MJ-4309-1, NSC-759108, Oxybutynin chloride, Oxybutynin hydrochloride, Pollakisu, Tropax', 'linkedDiseasesDrug_string': 'Overactive Bladder (EFO_1000781), Urinary Incontinence (HP_0000020), Prostate Carcinoma (EFO_0001663)', 'yearOfFirstApproval': 1975, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM2 (ENSG00000181072)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.92 | Q17 | What gene does the drug Enmd-2076 target? | The drug Enmd-2076 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 7 genes: FGFR3, FLT3, KIT, KDR, AURKB, CSF1R and AURKA | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%enmd-2076%" OR LOWER(tradeNames_string) LIKE "%enmd-2076%" OR LOWER(drugSynonyms_string) LIKE "%enmd-2076%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5432', 'drugName': 'Enmd-2076', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD-2076, Enmd 2076, Enmd-2076', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Clear Cell Adenocarcinoma (EFO_0000348), Fallopian Tube Carcinoma (EFO_1000251), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR3 (ENSG00000068078), AURKB (ENSG00000178999), CSF1R (ENSG00000182578), AURKA (ENSG00000087586)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_2122', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2123', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2124', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2126', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_2121', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_5430', 'drugName': 'Enmd-2076', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD-2076, Enmd 2076, Enmd-2076', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Clear Cell Adenocarcinoma (EFO_0000348), Fallopian Tube Carcinoma (EFO_1000251), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR3 (ENSG00000068078), AURKB (ENSG00000178999), CSF1R (ENSG00000182578), AURKA (ENSG00000087586)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_5428', 'drugName': 'Enmd-2076', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD-2076, Enmd 2076, Enmd-2076', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Clear Cell Adenocarcinoma (EFO_0000348), Fallopian Tube Carcinoma (EFO_1000251), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR3 (ENSG00000068078), AURKB (ENSG00000178999), CSF1R (ENSG00000182578), AURKA (ENSG00000087586)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_5427', 'drugName': 'Enmd-2076', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD-2076, Enmd 2076, Enmd-2076', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Clear Cell Adenocarcinoma (EFO_0000348), Fallopian Tube Carcinoma (EFO_1000251), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR3 (ENSG00000068078), AURKB (ENSG00000178999), CSF1R (ENSG00000182578), AURKA (ENSG00000087586)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_2125', 'drugName': 'Enmd-981693', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD 981693, ENMD-2076, ENMD-981693, Enmd-2076 free base, Enmd-981693, MKC-1, Mkc 1, R-440, RO 31-7453, RO-31-7453, Ro-317453', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Cancer (MONDO_0004992), Breast Cancer (MONDO_0007254), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Colorectal Carcinoma (EFO_1001951)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KDR (ENSG00000128052), FYN (ENSG00000010810), SRC (ENSG00000197122), LCK (ENSG00000182866), YES1 (ENSG00000176105), BLK (ENSG00000136573), HCK (ENSG00000101336), LYN (ENSG00000254087), FRK (ENSG00000111816), FGR (ENSG00000000938), SRMS (ENSG00000125508), FLT3 (ENSG00000122025), PDGFRB (ENSG00000113721), PDGFRA (ENSG00000134853), AURKA (ENSG00000087586), FGFR3 (ENSG00000068078), FGFR1 (ENSG00000077782), FGFR4 (ENSG00000160867), FGFR2 (ENSG00000066468)', 'numberLinkedTargets': 19}, {'UUID': 'DrugGeneTargets_v2_5433', 'drugName': 'Enmd-2076', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD-2076, Enmd 2076, Enmd-2076', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Clear Cell Adenocarcinoma (EFO_0000348), Fallopian Tube Carcinoma (EFO_1000251), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR3 (ENSG00000068078), AURKB (ENSG00000178999), CSF1R (ENSG00000182578), AURKA (ENSG00000087586)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_5431', 'drugName': 'Enmd-2076', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD-2076, Enmd 2076, Enmd-2076', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Clear Cell Adenocarcinoma (EFO_0000348), Fallopian Tube Carcinoma (EFO_1000251), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR3 (ENSG00000068078), AURKB (ENSG00000178999), CSF1R (ENSG00000182578), AURKA (ENSG00000087586)', 'numberLinkedTargets': 7}, {'UUID': 'DrugGeneTargets_v2_5429', 'drugName': 'Enmd-2076', 'tradeNames_string': '', 'drugSynonyms_string': 'ENMD-2076, Enmd 2076, Enmd-2076', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Clear Cell Adenocarcinoma (EFO_0000348), Fallopian Tube Carcinoma (EFO_1000251), Multiple Myeloma (EFO_0001378), Breast Cancer (MONDO_0007254), Hepatocellular Carcinoma (EFO_0000182), Soft Tissue Sarcoma (EFO_1001968), Peritoneum Cancer (MONDO_0002087), Ovarian Cancer (MONDO_0008170), Lymphoid Neoplasm (EFO_0001642)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'KIT (ENSG00000157404), KDR (ENSG00000128052), FLT3 (ENSG00000122025), FGFR3 (ENSG00000068078), AURKB (ENSG00000178999), CSF1R (ENSG00000182578), AURKA (ENSG00000087586)', 'numberLinkedTargets': 7}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.855 | Q17 | What gene does the drug Pantoprazole target? | The drug Pantoprazole targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pantoprazole%" OR LOWER(tradeNames_string) LIKE "%pantoprazole%" OR LOWER(drugSynonyms_string) LIKE "%pantoprazole%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1903', 'drugName': 'Pantoprazole Sodium', 'tradeNames_string': 'Pantoprazole sodium, Protonix, Protonix iv', 'drugSynonyms_string': 'Controloc control, Pantoprazole (as sodium), Pantoprazole sodium, Pantoprazole sodium hydrate, Pantoprazole sodium sesquihydrate, Pantozol control, Somac control', 'linkedDiseasesDrug_string': 'Esophagitis (HP_0100633), Neoplasm (EFO_0000616), Fish-Eye Disease (Orphanet_79292), Zollinger-Ellison Syndrome (EFO_0007549), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4835', 'drugName': 'Pantoprazole', 'tradeNames_string': 'Pantoloc control, Protium, Protium i.v.', 'drugSynonyms_string': 'Altopan, BY 1023, BY-1023, NSC-759257, Pantocid, Pantoloc, Pantoprazole, Pantozol, Protonix, SK&F 96022, SK&F-96022, SK-96022, SKF-96022, Zovanta', 'linkedDiseasesDrug_string': "Diabetes Mellitus (EFO_0000400), Multiple Sclerosis (MONDO_0005301), Hemorrhage (MP_0001914), Bacterial Disease (EFO_0000771), Congestive Heart Failure (EFO_0000373), Prostate Cancer (MONDO_0008315), Gastrin-Producing Neuroendocrine Tumor (MONDO_0003523), Laryngopharyngeal Reflux (EFO_1001355), Fish-Eye Disease (Orphanet_79292), Acute Coronary Syndrome (EFO_0005672), Esophageal Disease (EFO_0009544), Ulcer Disease (MONDO_0043839), Peptic Ulcer (HP_0004398), Helicobacter Pylori Infectious Disease (EFO_1000961), Aspergillosis (EFO_0007157), Barrett'S Esophagus (EFO_0000280), Gastroesophageal Reflux Disease (EFO_0003948), Esophagitis (HP_0100633), Neoplasm (EFO_0000616), Zollinger-Ellison Syndrome (EFO_0007549), Gastrointestinal Hemorrhage (HP_0002239), Type 1 Diabetes Mellitus (MONDO_0005147), Type 2 Diabetes Mellitus (MONDO_0005148), Schizophrenia (MONDO_0005090)", 'yearOfFirstApproval': 2000, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1521 | Q17 | What gene does the drug Vonoprazan target? | The drug Vonoprazan targets 2 genes: ATP4B and ATP4A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%vonoprazan%" OR LOWER(tradeNames_string) LIKE "%vonoprazan%" OR LOWER(drugSynonyms_string) LIKE "%vonoprazan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5640', 'drugName': 'Vonoprazan Fumarate', 'tradeNames_string': '', 'drugSynonyms_string': 'TAK-438, TAK-438 monofumarate, Tak 438, Vonoprazan fumarate, Vonoprazan fumurate, Vonoprazan monofumarate', 'linkedDiseasesDrug_string': 'Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Gastroesophageal Reflux Disease (EFO_0003948), Helicobacter Pylori Infectious Disease (EFO_1000961)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5499', 'drugName': 'Vonoprazan', 'tradeNames_string': 'Takecab, Vocinti', 'drugSynonyms_string': 'TAK-438, Vonoprazan', 'linkedDiseasesDrug_string': 'Gastric Ulcer (EFO_0009454), Duodenal Ulcer (EFO_0004607), Peptic Ulcer (HP_0004398), Helicobacter Pylori Infectious Disease (EFO_1000961), Gastroesophageal Reflux Disease (EFO_0003948)', 'yearOfFirstApproval': 2022, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ATP4A (ENSG00000105675), ATP4B (ENSG00000186009)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1918 | Q17 | What gene does the drug Migalastat Hydrochloride target? | The drug Migalastat Hydrochloride targets the gene GLA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%migalastat hydrochloride%" OR LOWER(tradeNames_string) LIKE "%migalastat hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%migalastat hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_549', 'drugName': 'Migalastat Hydrochloride', 'tradeNames_string': 'Galafold', 'drugSynonyms_string': 'AT-1001 (MIGALASTAT HYDROCHLORIDE), Migalastat hcl, Migalastat hydrochloride', 'linkedDiseasesDrug_string': 'Fabry Disease (MONDO_0010526)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GLA (ENSG00000102393)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.760 | Q17 | What gene does the drug Obinutuzumab target? | The drug Obinutuzumab targets the gene MS4A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%obinutuzumab%" OR LOWER(tradeNames_string) LIKE "%obinutuzumab%" OR LOWER(drugSynonyms_string) LIKE "%obinutuzumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_847', 'drugName': 'Obinutuzumab', 'tradeNames_string': 'Gazyvaro', 'drugSynonyms_string': 'AFUTUZUMAB, Afutuzumab, GA-101, GA101, Gazyva, HUMAB<CD20>, HUMABCD20, Obinutuzumab, R-7159, RG-7159, RO 5072759, RO 5072759 HUMAB<CD20>, RO-5072759, RO-5072759 HUMAB<CD20>, Ro5072759', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Graft Versus Host Disease (MONDO_0013730), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Colorectal Carcinoma (EFO_1001951), Focal Segmental Glomerulosclerosis (EFO_0004236), Mantle Cell Lymphoma (EFO_1001469), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Mycosis Fungoides (EFO_1001051), Diffuse Large B-Cell Lymphoma (EFO_0000403), Neoplasm Of Mature B-Cells (EFO_0000096), Waldenstrom Macroglobulinemia (EFO_0009441), Hairy Cell Leukemia (EFO_1000956), Hodgkins Lymphoma (EFO_0000183), Prolymphocytic Leukemia (MONDO_0001023), Chronic Kidney Disease (EFO_0003884), Follicular Lymphoma (MONDO_0018906), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Non-Small Cell Lung Carcinoma (EFO_0003060), Kidney Disease (EFO_0003086), Lupus Nephritis (EFO_0005761)', 'yearOfFirstApproval': 2013, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.504 | Q17 | What gene does the drug Pentaerythritol Tetranitrate target? | The drug Pentaerythritol Tetranitrate targets 4 genes: GUCY1A1, GUCY1B2, GUCY1A2 and GUCY1B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentaerythritol tetranitrate%" OR LOWER(tradeNames_string) LIKE "%pentaerythritol tetranitrate%" OR LOWER(drugSynonyms_string) LIKE "%pentaerythritol tetranitrate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_31', 'drugName': 'Pentaerythritol Tetranitrate', 'tradeNames_string': 'Cardiacap, Mycardol, Pentritol tempules, Peritrate, Peritrate sa', 'drugSynonyms_string': 'Pentaerithritol tetranitrate, Pentaerithrityl tetranitrate, Pentaerythritol tetranitrate, Pentaerythrityl tetranitrate, Pentalong, Pentanitrol', 'linkedDiseasesDrug_string': 'Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GUCY1B1 (ENSG00000061918), GUCY1B2 (ENSG00000123201), GUCY1A2 (ENSG00000152402), GUCY1A1 (ENSG00000164116)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1287 | Q17 | What gene does the drug Encainide Hydrochloride target? | The drug Encainide Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%encainide hydrochloride%" OR LOWER(tradeNames_string) LIKE "%encainide hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%encainide hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6219', 'drugName': 'Encainide Hydrochloride', 'tradeNames_string': 'Enkaid', 'drugSynonyms_string': 'Encainide hcl, Encainide hydrochloride, MJ 9067-1, MJ-9067, MJ-9067-1', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1986, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1340 | Q17 | What gene does the drug Levocetirizine target? | The drug Levocetirizine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%levocetirizine%" OR LOWER(tradeNames_string) LIKE "%levocetirizine%" OR LOWER(drugSynonyms_string) LIKE "%levocetirizine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5631', 'drugName': 'Levocetirizine Dihydrochloride', 'tradeNames_string': 'Levocetirizine dihydrochloride, Xusal, Xyzal, Xyzal allergy 24hr, Xyzall', 'drugSynonyms_string': 'Cetirizine (r)-form dihydrochloride, Cetirizine hydrochloride (r)-, Levocetirizine dihydrochloride, Levocetirizine hydrochloride, Levocetirizine monohydrochloride, NSC-758898, UCB 28556, UCB-28556', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Cough (HP_0012735), Fish-Eye Disease (Orphanet_79292), Urticaria (EFO_0005531), Pruritus (HP_0000989), Rhinitis (EFO_0008521)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_491', 'drugName': 'Levocetirizine', 'tradeNames_string': 'Xyzal', 'drugSynonyms_string': '(-)-cetirizine, (r)-cetirizine, Cetirizine (r)-form, Cetirizine, (-)-, Cetirizine, (r)-, Levocetirizine, Xazal', 'linkedDiseasesDrug_string': 'Allergic Conjunctivitis (EFO_0007141), Eczema (HP_0000964), Asthma (MONDO_0004979), Rhinitis, Allergic, Perennial (EFO_1001417), Seasonal Allergic Rhinitis (EFO_0003956), Colorectal Neoplasm (EFO_0004142), Atopic Eczema (EFO_0000274), Cough (HP_0012735), Fish-Eye Disease (Orphanet_79292), Vasomotor Rhinitis (EFO_0007533), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531), Pruritus (HP_0000989), Rhinitis (EFO_0008521), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 2007, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.12 | Q17 | What gene does the drug Propafenone Hydrochloride target? | The drug Propafenone Hydrochloride targets 12 genes: SCN1A, ADRB1, SCN7A, SCN9A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A, SCN3A and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%propafenone hydrochloride%" OR LOWER(tradeNames_string) LIKE "%propafenone hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%propafenone hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2587', 'drugName': 'Propafenone Hydrochloride', 'tradeNames_string': 'Arythmol, Propafenone hydrochloride, Rythmol, Rythmol sr, Rytmonorm', 'drugSynonyms_string': 'NSC-758640, Propafenone hcl, Propafenone hydrochloride', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 12}, {'UUID': 'DrugGeneTargets_v2_2588', 'drugName': 'Propafenone Hydrochloride', 'tradeNames_string': 'Arythmol, Propafenone hydrochloride, Rythmol, Rythmol sr, Rytmonorm', 'drugSynonyms_string': 'NSC-758640, Propafenone hcl, Propafenone hydrochloride', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 12}, {'UUID': 'DrugGeneTargets_v2_2589', 'drugName': 'Propafenone Hydrochloride', 'tradeNames_string': 'Arythmol, Propafenone hydrochloride, Rythmol, Rythmol sr, Rytmonorm', 'drugSynonyms_string': 'NSC-758640, Propafenone hcl, Propafenone hydrochloride', 'linkedDiseasesDrug_string': 'Ventricular Arrhythmia (HP_0004308), Heart Failure (EFO_0003144), Atrial Fibrillation (EFO_0000275)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB1 (ENSG00000043591), ADRB2 (ENSG00000169252), SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 12}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.402 | Q17 | What gene does the drug Tamsulosin Hydrochloride target? | The drug Tamsulosin Hydrochloride targets 3 genes: ADRA1D, ADRA1B and ADRA1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tamsulosin hydrochloride%" OR LOWER(tradeNames_string) LIKE "%tamsulosin hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%tamsulosin hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5784', 'drugName': 'Tamsulosin Hydrochloride', 'tradeNames_string': 'Alphacard mr, Bazetham mr, Contiflo xl, Cositam xl, Diffundox, Faramsil, Flectone xl, Flomax, Flomax mr, Flomax relief mr, Flomaxtra xl, Galebon, Losinate mr, Maxtron, Morvesin xl, Omnic mr, Pamsvax xl, Petyme, Pinexel pr, Prosurin xl, Stronazon, Tabphyn mr, Tamfrex xl, Tamsulosin hydrochloride, Tamurex', 'drugSynonyms_string': 'Harnal, LY-253351, LY253351, R-(-)-YM-12617, Tamsulosin hcl, Tamsulosin hydrochloride, YM-12617-1, YM-617, YM617', 'linkedDiseasesDrug_string': 'Urinary Retention (HP_0000016), Post-Operative Sign Or Symptom (EFO_0005323), Hypertension (EFO_0000537), Benign Prostatic Hyperplasia (EFO_0000284), Prostatitis (EFO_0003830), Neurogenic Bladder (HP_0000011), Prostate Carcinoma (EFO_0001663)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.288 | Q17 | What gene does the drug Elzasonan Hydrochloride target? | The drug Elzasonan Hydrochloride is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: HTR1B and HTR1D | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%elzasonan hydrochloride%" OR LOWER(tradeNames_string) LIKE "%elzasonan hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%elzasonan hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3748', 'drugName': 'Elzasonan Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-448,187-01, Cp-448187-01, Elzasonan hcl, Elzasonan hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3749', 'drugName': 'Elzasonan Hydrochloride', 'tradeNames_string': '', 'drugSynonyms_string': 'CP-448,187-01, Cp-448187-01, Elzasonan hcl, Elzasonan hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR1B (ENSG00000135312), HTR1D (ENSG00000179546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1075 | Q17 | What gene does the drug Salmeterol Xinafoate target? | The drug Salmeterol Xinafoate targets the gene ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%salmeterol xinafoate%" OR LOWER(tradeNames_string) LIKE "%salmeterol xinafoate%" OR LOWER(drugSynonyms_string) LIKE "%salmeterol xinafoate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4540', 'drugName': 'Salmeterol Xinafoate', 'tradeNames_string': 'Serevent', 'drugSynonyms_string': 'GR 33343 G, GR-33343 G, GR-33343X, LIPO-202, Salmeterol 1-hydroxy-2-naphthoate, Salmeterol xinafoate', 'linkedDiseasesDrug_string': 'Chronic Bronchitis (EFO_0006505), Bronchospasm (HP_0025428), Asthma (MONDO_0004979), Obesity (EFO_0001073), Chronic Obstructive Pulmonary Disease (EFO_0000341), Emphysema (EFO_0000464), Bronchiolitis Obliterans (EFO_0007183)', 'yearOfFirstApproval': 1994, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1201 | Q17 | What gene does the drug Cimetidine target? | The drug Cimetidine targets the gene HRH2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cimetidine%" OR LOWER(tradeNames_string) LIKE "%cimetidine%" OR LOWER(drugSynonyms_string) LIKE "%cimetidine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_165', 'drugName': 'Cimetidine', 'tradeNames_string': 'Acid-eze, Acitak 200, Acitak 400, Acitak 800, Brumetadina, Cimetidine, Dyspamet, Galenamet, Kentamet, Peptimax 200, Peptimax 400, Peptimax 800, Tagadine, Tagamet, Tagamet 100, Tagamet hb, Tagamet hb 200, Ultec, Valmagen, Zita', 'drugSynonyms_string': 'Aciloc, Acinil, Brumetidina, Cimal, Cimetidine, Cimetidinum, Gastromet, NSC-335308, SKF-92334, Stomedine, Ulcedin, Ulcimet, Ulcomedina', 'linkedDiseasesDrug_string': 'Infection (EFO_0000544), Amyotrophic Lateral Sclerosis (MONDO_0004976), Hemorrhage (MP_0001914), Gastrointestinal Hemorrhage (HP_0002239), Atopic Eczema (EFO_0000274), Chronic Obstructive Pulmonary Disease (EFO_0000341), Generalized Anxiety Disorder (EFO_1001892), Duodenal Ulcer (EFO_0004607), Ulcer Disease (MONDO_0043839), Erythropoietic Protoporphyria (MONDO_0001676), Peptic Ulcer (HP_0004398), Endometrial Cancer (MONDO_0011962), Gastroesophageal Reflux Disease (EFO_0003948), Breast Carcinoma In Situ (MONDO_0004658)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_4862', 'drugName': 'Cimetidine Hydrochloride', 'tradeNames_string': 'Cimetidine hydrochloride, Tagamet', 'drugSynonyms_string': 'Cimetidine hcl, Cimetidine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH2 (ENSG00000113749)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1746 | Q17 | What gene does the drug Patritumab Deruxtecan target? | The drug Patritumab Deruxtecan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target 2 genes: TOP1 and ERBB3 | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%patritumab deruxtecan%" OR LOWER(tradeNames_string) LIKE "%patritumab deruxtecan%" OR LOWER(drugSynonyms_string) LIKE "%patritumab deruxtecan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1952', 'drugName': 'Patritumab Deruxtecan', 'tradeNames_string': '', 'drugSynonyms_string': 'Patritumab deruxtecan, U3 1402, U3-1402, U3-1402A', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361), TOP1 (ENSG00000198900)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_1953', 'drugName': 'Patritumab Deruxtecan', 'tradeNames_string': '', 'drugSynonyms_string': 'Patritumab deruxtecan, U3 1402, U3-1402, U3-1402A', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Breast Cancer (MONDO_0007254)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'ERBB3 (ENSG00000065361), TOP1 (ENSG00000198900)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.697 | Q17 | What gene does the drug Tetrahydrozoline Hydrochloride target? | The drug Tetrahydrozoline Hydrochloride targets 6 genes: ADRA2A, ADRA2C, ADRA1A, ADRA1D, ADRA2B and ADRA1B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tetrahydrozoline hydrochloride%" OR LOWER(tradeNames_string) LIKE "%tetrahydrozoline hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%tetrahydrozoline hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1295', 'drugName': 'Tetrahydrozoline Hydrochloride', 'tradeNames_string': 'Tyzine', 'drugSynonyms_string': 'NSC-757339, Tetrahydrozoline hydrochloride, Tetrahydrozoline nitrate, Tetryzoline, Tetryzoline hydrochloride', 'linkedDiseasesDrug_string': 'Pterygium (EFO_0000678), Inflammation (MP_0001845)', 'yearOfFirstApproval': 1979, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRA1A (ENSG00000120907), ADRA2A (ENSG00000150594), ADRA2C (ENSG00000184160), ADRA1D (ENSG00000171873), ADRA1B (ENSG00000170214), ADRA2B (ENSG00000274286)', 'numberLinkedTargets': 6}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1632 | Q17 | What gene does the drug Methysergide Maleate target? | The drug Methysergide Maleate targets 3 genes: HTR2C, HTR1A and HTR2B. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methysergide maleate%" OR LOWER(tradeNames_string) LIKE "%methysergide maleate%" OR LOWER(drugSynonyms_string) LIKE "%methysergide maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2806', 'drugName': 'Methysergide Maleate', 'tradeNames_string': 'Sansert', 'drugSynonyms_string': 'Methysergide hydrogen maleate, Methysergide maleate, NSC-759143', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2B (ENSG00000135914), HTR1A (ENSG00000178394)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2807', 'drugName': 'Methysergide Maleate', 'tradeNames_string': 'Sansert', 'drugSynonyms_string': 'Methysergide hydrogen maleate, Methysergide maleate, NSC-759143', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2B (ENSG00000135914), HTR1A (ENSG00000178394)', 'numberLinkedTargets': 3}, {'UUID': 'DrugGeneTargets_v2_2808', 'drugName': 'Methysergide Maleate', 'tradeNames_string': 'Sansert', 'drugSynonyms_string': 'Methysergide hydrogen maleate, Methysergide maleate, NSC-759143', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1962, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2C (ENSG00000147246), HTR2B (ENSG00000135914), HTR1A (ENSG00000178394)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1877 | Q17 | What gene does the drug Methyprylon target? | The drug Methyprylon targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methyprylon%" OR LOWER(tradeNames_string) LIKE "%methyprylon%" OR LOWER(drugSynonyms_string) LIKE "%methyprylon%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1441', 'drugName': 'Methyprylon', 'tradeNames_string': 'Noludar', 'drugSynonyms_string': 'Methyprylon, NSC-30442', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.696 | Q17 | What gene does the drug Crovalimab target? | The drug Crovalimab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene C5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%crovalimab%" OR LOWER(tradeNames_string) LIKE "%crovalimab%" OR LOWER(drugSynonyms_string) LIKE "%crovalimab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3907', 'drugName': 'Crovalimab', 'tradeNames_string': '', 'drugSynonyms_string': 'Crovalimab, RG-6107, RG6107, RO-7112689, RO7112689, Ro7112689, SKY-59, SKY59', 'linkedDiseasesDrug_string': 'Sickle Cell Anemia (MONDO_0011382), Atypical Hemolytic-Uremic Syndrome (MONDO_0016244), Guillain-Barre Syndrome (EFO_0007292)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'C5 (ENSG00000106804)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.858 | Q17 | What gene does the drug Methapyrilene Hydrochloride target? | The drug Methapyrilene Hydrochloride targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methapyrilene hydrochloride%" OR LOWER(tradeNames_string) LIKE "%methapyrilene hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%methapyrilene hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2856', 'drugName': 'Methapyrilene Hydrochloride', 'tradeNames_string': 'Thenylene hydrochloride', 'drugSynonyms_string': 'Methapyrilene hcl, Methapyrilene hydrochloride, NSC-758410, Thenylpyramine hydrochloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.162 | Q17 | What gene does the drug Clozapine target? | The drug Clozapine targets 2 genes: HTR2A and DRD2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clozapine%" OR LOWER(tradeNames_string) LIKE "%clozapine%" OR LOWER(drugSynonyms_string) LIKE "%clozapine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3784', 'drugName': 'Clozapine', 'tradeNames_string': 'Clozapine, Clozaril, Fazaclo, Fazaclo odt, Versacloz, Zaponex', 'drugSynonyms_string': 'Clozapine, Clozapine (caraco), Clozapine (clozaril), Clozapine (fazaclo), Clozapine (ivax), Clozapine (mylan), Clozapine (teva), Clozapine (udl), Clozapine (versacloz), Clozapine resolution mixture, HF 1854, HF-1854, Leponex, NSC-757429', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Intellectual Disability (HP_0001249), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Developmental Disability (EFO_0003852), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3785', 'drugName': 'Clozapine', 'tradeNames_string': 'Clozapine, Clozaril, Fazaclo, Fazaclo odt, Versacloz, Zaponex', 'drugSynonyms_string': 'Clozapine, Clozapine (caraco), Clozapine (clozaril), Clozapine (fazaclo), Clozapine (ivax), Clozapine (mylan), Clozapine (teva), Clozapine (udl), Clozapine (versacloz), Clozapine resolution mixture, HF 1854, HF-1854, Leponex, NSC-757429', 'linkedDiseasesDrug_string': 'Psychosis (EFO_0005407), Intellectual Disability (HP_0001249), Dementia (HP_0000726), Schizoaffective Disorder (EFO_0005411), Anxiety (EFO_0005230), Developmental Disability (EFO_0003852), Bipolar Disorder (MONDO_0004985), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1989, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HTR2A (ENSG00000102468), DRD2 (ENSG00000149295)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.902 | Q17 | What gene does the drug Pancuronium Bromide target? | The drug Pancuronium Bromide targets 5 genes: CHRNB1, CHRNA1, CHRND, CHRNE and CHRNG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pancuronium bromide%" OR LOWER(tradeNames_string) LIKE "%pancuronium bromide%" OR LOWER(drugSynonyms_string) LIKE "%pancuronium bromide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6111', 'drugName': 'Pancuronium Bromide', 'tradeNames_string': 'Mioblock, Pancuronium bromide, Pavulon', 'drugSynonyms_string': 'Bromurex, Mioblock, NSC-293162, ORG NA 97, ORG-NA 97, ORG-NA-97, Pancuronium bromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1972, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4193', 'drugName': 'Vecuronium Bromide', 'tradeNames_string': 'Musculax, Norcuron, Vecuronium bromide', 'drugSynonyms_string': 'NSC-759184, ORG NC 45, ORG-NC 45, Pancuronium bromide impurity, vecuronium bromide -, Vecuronium bromide', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1984, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNA1 (ENSG00000138435), CHRNG (ENSG00000196811), CHRNB1 (ENSG00000170175), CHRND (ENSG00000135902), CHRNE (ENSG00000108556)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1576 | Q17 | What gene does the drug Peginterferon Alfa-2A target? | The drug Peginterferon Alfa-2A targets 2 genes: IFNAR1 and IFNAR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%peginterferon alfa-2a%" OR LOWER(tradeNames_string) LIKE "%peginterferon alfa-2a%" OR LOWER(drugSynonyms_string) LIKE "%peginterferon alfa-2a%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3511', 'drugName': 'Peginterferon Alfa-2A', 'tradeNames_string': 'Pegasys, Roferon-A', 'drugSynonyms_string': 'Peg-interferon alfa 2a, Peg-interferon alfa-2a, Peginterferon .alpha.-2a, Peginterferon alfa, Peginterferon alfa-2a, Peginterferon-alfa-2a, Pegyinterferon-alfa-2a, Pegylated interferon alfa-2a, Pegylated interferon alpha 2a, Pegylated-interferon alfa 2a, Pegylated-interferon-alfa-2a, RO 25-8310/000, RO-258310000', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Primary Myelofibrosis (EFO_0002430), Infection (EFO_0000544), Chronic Lymphocytic Leukemia (EFO_0000095), Essential Thrombocythemia (EFO_0000479), Polycythemia Vera (EFO_0002429), Chronic Myelogenous Leukemia (EFO_0000339), Malignant Colon Neoplasm (MONDO_0021063), Hepatitis C Virus Infection (EFO_0003047), Hepatocellular Carcinoma (EFO_0000182), Breast Cancer (MONDO_0007254), Chronic Hepatitis B Virus Infection (EFO_0004239), Hepatitis B Virus Infection (EFO_0004197), Myelofibrosis (MONDO_0044903), Hepatitis D Virus Infection (EFO_0007304), Thrombocytopenia (HP_0001873), Chronic Hepatitis C Virus Infection (EFO_0004220), Depressive Disorder (MONDO_0002050), Commensal Clostridium Infectious Disease (EFO_1000874), Diffuse Intrinsic Pontine Glioma (EFO_1000026), Hiv Infection (EFO_0000764), Neoplasm (EFO_0000616), Hepatitis (HP_0012115), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Chronic Hepatitis (EFO_0008496), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 2002, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IFNAR1 (ENSG00000142166), IFNAR2 (ENSG00000159110)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.260 | Q17 | What gene does the drug Bosentan target? | The drug Bosentan targets 2 genes: EDNRA and EDNRB. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bosentan%" OR LOWER(tradeNames_string) LIKE "%bosentan%" OR LOWER(drugSynonyms_string) LIKE "%bosentan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_379', 'drugName': 'Bosentan', 'tradeNames_string': 'Tracleer', 'drugSynonyms_string': 'Anhydrous bosentan, Bosentan, Bosentan anhydrous, Bosentan hydrate, Bosentan monohydrate, RO 47-0203/029, RO-47-0203-029, RO-470203029', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Eisenmenger Syndrome (EFO_0009200), Pulmonary Hypertension (MONDO_0005149), Pulmonary Arterial Hypertension (EFO_0001361), Glaucoma (MONDO_0005041), Idiopathic Pulmonary Fibrosis (EFO_0000768), Anterior Ischemic Optic Neuropathy (EFO_1000809), Congestive Heart Failure (EFO_0000373), Hypertension (EFO_0000537), Persistent Fetal Circulation Syndrome (EFO_1001103), Hypoplastic Left Heart Syndrome (MONDO_0004933), Ulcer Disease (MONDO_0043839), Pancreatic Carcinoma (EFO_0002618), Asthma (MONDO_0004979), Fever (HP_0001945), Chronic Obstructive Pulmonary Disease (EFO_0000341), Hepatopulmonary Syndrome (EFO_1001346), Systemic Scleroderma (EFO_0000717), Congenital Heart Disease (EFO_0005207), Sleep Apnea (EFO_0003877), Neoplasm (EFO_0000616), Idiopathic And/Or Familial Pulmonary Arterial Hypertension (MONDO_0008347), Melanoma (EFO_0000756), Type 2 Diabetes Mellitus (MONDO_0005148), Mitral Valve Stenosis (EFO_0007372), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EDNRB (ENSG00000136160), EDNRA (ENSG00000151617)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.339 | Q17 | What gene does the drug Mitoxantrone target? | The drug Mitoxantrone targets the gene TOP2A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mitoxantrone%" OR LOWER(tradeNames_string) LIKE "%mitoxantrone%" OR LOWER(drugSynonyms_string) LIKE "%mitoxantrone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4715', 'drugName': 'Mitoxantrone Hydrochloride', 'tradeNames_string': 'Mitoxantrone hydrochloride, Novantrone', 'drugSynonyms_string': 'CL 232,315, CL-232315, Mitoxantrone Dihcl, Mitoxantrone Dihydrochloride, Mitoxantrone dihydrochloride, Mitoxantrone hcl, Mitoxantrone hydrochloride, Mitozantrone, NSC-301739', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Myelodysplastic Syndrome (EFO_0000198), Prostate Carcinoma (EFO_0001663), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Chronic Myelogenous Leukemia (EFO_0000339), Myeloid Sarcoma (EFO_1001052), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Diffuse Large B-Cell Lymphoma (EFO_0000403), Gastric Carcinoma (EFO_0000178), Secondary Progressive Multiple Sclerosis (EFO_0008522), Granulocytic Sarcoma (EFO_1000286), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoid Leukemia (EFO_0004289), Prolymphocytic Leukemia (MONDO_0001023), Head And Neck Malignant Neoplasia (EFO_0006859), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Myeloproliferative Disorder (EFO_0004251), Metastatic Prostate Cancer (EFO_0000196), Acute Monocytic Leukemia (EFO_0000221), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2577', 'drugName': 'Mitoxantrone', 'tradeNames_string': 'Mitoxantrone HCl, Novantrone', 'drugSynonyms_string': 'Misostol, Mitoxantrone, NSC-279836, Novantrone', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Multiple Sclerosis (MONDO_0005301), Pain (EFO_0003843), Central Nervous System Cancer (EFO_0000326), Myelodysplastic Syndrome (EFO_0000198), Chronic Myelogenous Leukemia (EFO_0000339), Ovarian Cancer (MONDO_0008170), Prostate Adenocarcinoma (EFO_0000673), Acute Promyelocytic Leukemia (EFO_0000224), Myeloid Sarcoma (EFO_1001052), Prostate Carcinoma (EFO_0001663), Hepatocellular Carcinoma (EFO_0000182), Prostate Cancer (MONDO_0008315), Mantle Cell Lymphoma (EFO_1001469), Breast Cancer (MONDO_0007254), Acute Lymphoblastic Leukemia (EFO_0000220), Lymphoma (EFO_0000574), Acute Myeloid Leukemia (EFO_0000222), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Acute Leukemia Of Ambiguous Lineage (MONDO_0019460), Diffuse Large B-Cell Lymphoma (EFO_0000403), Gastric Carcinoma (EFO_0000178), Secondary Progressive Multiple Sclerosis (EFO_0008522), Pancreatic Carcinoma (EFO_0002618), Granulocytic Sarcoma (EFO_1000286), Extranodal Nasal Nk/T Cell Lymphoma (MONDO_0019472), Precursor T-Cell Lymphoblastic Leukemia-Lymphoma (EFO_1001830), Lymphoblastic Lymphoma (MONDO_0000873), Soft Tissue Sarcoma (EFO_1001968), Lymphoid Leukemia (EFO_0004289), Prolymphocytic Leukemia (MONDO_0001023), Head And Neck Malignant Neoplasia (EFO_0006859), Follicular Lymphoma (MONDO_0018906), Leukemia (EFO_0000565), Neoplasm (EFO_0000616), T-Cell Non-Hodgkin Lymphoma (MONDO_0015760), Myeloproliferative Disorder (EFO_0004251), Metastatic Prostate Cancer (EFO_0000196), Acute Monocytic Leukemia (EFO_0000221), Unspecified Peripheral T-Cell Lymphoma (EFO_0000211)', 'yearOfFirstApproval': 1987, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TOP2A (ENSG00000131747)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1881 | Q17 | What gene does the drug Tridihexethyl target? | The drug Tridihexethyl targets 2 genes: CHRM1 and CHRM3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tridihexethyl%" OR LOWER(tradeNames_string) LIKE "%tridihexethyl%" OR LOWER(drugSynonyms_string) LIKE "%tridihexethyl%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5885', 'drugName': 'Tridihexethyl', 'tradeNames_string': '', 'drugSynonyms_string': 'Tridihexethyl, Tridihexethyl cation, Tridihexethyl ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5884', 'drugName': 'Tridihexethyl', 'tradeNames_string': '', 'drugSynonyms_string': 'Tridihexethyl, Tridihexethyl cation, Tridihexethyl ion', 'linkedDiseasesDrug_string': 'Gastrointestinal Disease (EFO_0010282)', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM3 (ENSG00000133019), CHRM1 (ENSG00000168539)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5749', 'drugName': 'Tridihexethyl Chloride', 'tradeNames_string': 'Pathilon', 'drugSynonyms_string': 'Tridihexethyl chloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5748', 'drugName': 'Tridihexethyl Chloride', 'tradeNames_string': 'Pathilon', 'drugSynonyms_string': 'Tridihexethyl chloride', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1954, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRM1 (ENSG00000168539), CHRM3 (ENSG00000133019)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1048 | Q17 | What gene does the drug Ponatinib target? | The drug Ponatinib targets 2 genes: BCR and ABL1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ponatinib%" OR LOWER(tradeNames_string) LIKE "%ponatinib%" OR LOWER(drugSynonyms_string) LIKE "%ponatinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2277', 'drugName': 'Ponatinib', 'tradeNames_string': 'Iclusig', 'drugSynonyms_string': 'AP-24534, AP24534, Ponatinib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Thyroid Neoplasm (EFO_0003841), Lung Adenocarcinoma (EFO_0000571), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Small Cell Lung Carcinoma (EFO_0000702), Neoplasm (EFO_0000616), Leukemia (EFO_0000565), Medullary Thyroid Gland Carcinoma (MONDO_0015277), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Lymphoblastic Leukemia (EFO_0000220), Gastrointestinal Stromal Tumor (MONDO_0011719), Acute Myeloid Leukemia (EFO_0000222), Glioblastoma Multiforme (EFO_0000519), Myelodysplastic Syndrome (EFO_0000198), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_6150', 'drugName': 'Ponatinib Hydrochloride', 'tradeNames_string': 'Iclusig', 'drugSynonyms_string': 'AP-24534 HCL, AP24534 HCL, Ponatinib hydrochloride', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Chronic Myelogenous Leukemia (EFO_0000339)', 'yearOfFirstApproval': 2012, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ABL1 (ENSG00000097007), BCR (ENSG00000186716)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.521 | Q17 | What gene does the drug Regrelor Disodium target? | The drug Regrelor Disodium is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene P2RY12. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%regrelor disodium%" OR LOWER(tradeNames_string) LIKE "%regrelor disodium%" OR LOWER(drugSynonyms_string) LIKE "%regrelor disodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3007', 'drugName': 'Regrelor Disodium', 'tradeNames_string': '', 'drugSynonyms_string': 'INS-50589, INS50589, Regrelor disodium', 'linkedDiseasesDrug_string': 'Coronary Artery Disease (EFO_0001645), Cardiovascular Disease (EFO_0000319)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'P2RY12 (ENSG00000169313)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1363 | Q17 | What gene does the drug Tiagabine target? | The drug Tiagabine targets the gene SLC6A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tiagabine%" OR LOWER(tradeNames_string) LIKE "%tiagabine%" OR LOWER(drugSynonyms_string) LIKE "%tiagabine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4422', 'drugName': 'Tiagabine', 'tradeNames_string': 'Gabitril', 'drugSynonyms_string': 'A-70569-1, ABBOTT-70569, ABBOTT-70569 FREE BASE, ABBOTT-70569-1, ABBOTT-705691 FREE BASE, ABT-569, ABT-569 FREE BASE, Gabitril, NNC-05-0328, NNC-050328 FREE BASE, NO-05-0328, NO-050328 FREE BASE, Tiagabine', 'linkedDiseasesDrug_string': 'Seizure (HP_0001250), Anxiety (EFO_0005230), Generalized Anxiety Disorder (EFO_1001892), Cocaine Dependence (EFO_0002610), Epilepsy (EFO_0000474), Obstructive Sleep Apnea (EFO_0003918), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A1 (ENSG00000157103)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3768', 'drugName': 'Tiagabine Hydrochloride', 'tradeNames_string': 'Gabitril, Tiagabine hydrochloride', 'drugSynonyms_string': 'ABBOTT-70569 HYDROCHLORIDE, ABBOTT-70569.1, ABBOTT-70569.HCL, ABBOTT-705691, ABT-569, Abbott-70569, Abbott-70569.1, NNC-05-0328, NNC-050328, NO-05-0328, NO-050328, Tiagabine hcl, Tiagabine hydrochloride', 'linkedDiseasesDrug_string': 'Anxiety (EFO_0005230), Generalized Anxiety Disorder (EFO_1001892), Seizure (HP_0001250)', 'yearOfFirstApproval': 1997, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A1 (ENSG00000157103)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1024 | Q17 | What gene does the drug Flurandrenolide target? | The drug Flurandrenolide targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%flurandrenolide%" OR LOWER(tradeNames_string) LIKE "%flurandrenolide%" OR LOWER(drugSynonyms_string) LIKE "%flurandrenolide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2820', 'drugName': 'Flurandrenolide', 'tradeNames_string': 'Cordran, Cordran sp, Flurandrenolide, Haelan, Haelan-c, Haelan-x', 'drugSynonyms_string': '33379, Fludroxicortide, Fludroxycortide, Flurandrenolide, Flurandrenolone, NSC-757869', 'linkedDiseasesDrug_string': 'Skin Disease (EFO_0000701), Chronic Kidney Disease (EFO_0003884)', 'yearOfFirstApproval': 1965, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.775 | Q17 | What gene does the drug Zopiclone target? | The drug Zopiclone targets 9 genes: GABRA5, GABRA4, GABRA3, GABRB2, GABRB3, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%zopiclone%" OR LOWER(tradeNames_string) LIKE "%zopiclone%" OR LOWER(drugSynonyms_string) LIKE "%zopiclone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_6180', 'drugName': 'Zopiclone', 'tradeNames_string': 'Zileze 3.75, Zileze 7.5, Zimovane, Zimovane ls', 'drugSynonyms_string': 'Amoban, Imovane, NSC-758463, RP 27267, RP-27267, Zopiclone', 'linkedDiseasesDrug_string': 'Sleep Disorder (EFO_0008568), Dementia (HP_0000726), Anxiety (EFO_0005230), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Obstructive Sleep Apnea (EFO_0003918), Insomnia (EFO_0004698), Schizophrenia (MONDO_0005090), Alcohol Drinking (EFO_0004329)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRA3 (ENSG00000011677), GABRB1 (ENSG00000163288), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 9}, {'UUID': 'DrugGeneTargets_v2_5294', 'drugName': 'Eszopiclone', 'tradeNames_string': 'Eszopiclone, Lunesta', 'drugSynonyms_string': '(S)-ZOPICLONE, (S)-Zopiclone, Estorra, Eszopiclon, Eszopiclone, Eszopiclone civ, GSK-1755165, Zopiclone s-form', 'linkedDiseasesDrug_string': 'Generalized Anxiety Disorder (EFO_1001892), Cannabis Dependence (EFO_0007191), Insomnia (EFO_0004698), Obstructive Sleep Apnea (EFO_0003918)', 'yearOfFirstApproval': 2004, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1748 | Q17 | What gene does the drug Lucatumumab target? | The drug Lucatumumab is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene CD40. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lucatumumab%" OR LOWER(tradeNames_string) LIKE "%lucatumumab%" OR LOWER(drugSynonyms_string) LIKE "%lucatumumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2640', 'drugName': 'Lucatumumab', 'tradeNames_string': '', 'drugSynonyms_string': 'CHIR-12.12, HCD-122, HCD122, Lucatumumab', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Follicular Lymphoma (MONDO_0018906), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'CD40 (ENSG00000101017)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.768 | Q17 | What gene does the drug Golodirsen target? | The drug Golodirsen targets the gene DMD. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%golodirsen%" OR LOWER(tradeNames_string) LIKE "%golodirsen%" OR LOWER(drugSynonyms_string) LIKE "%golodirsen%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4074', 'drugName': 'Golodirsen', 'tradeNames_string': 'Vyondys 53', 'drugSynonyms_string': 'Golodirsen, NG-12-0163, SRP-4053', 'linkedDiseasesDrug_string': 'Muscular Dystrophy (MONDO_0020121), Duchenne Muscular Dystrophy (MONDO_0010679)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'DMD (ENSG00000198947)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1256 | Q17 | What gene does the drug Bms-779788 target? | The drug Bms-779788 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene NR1H2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%bms-779788%" OR LOWER(tradeNames_string) LIKE "%bms-779788%" OR LOWER(drugSynonyms_string) LIKE "%bms-779788%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2568', 'drugName': 'Bms-779788', 'tradeNames_string': '', 'drugSynonyms_string': 'BMS 788, Bms-779788, EXEL 04286652, EXEL-04286652, XL 652, XL-014, XL-652', 'linkedDiseasesDrug_string': 'Atherosclerosis (EFO_0003914)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'NR1H2 (ENSG00000131408)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1213 | Q17 | What gene does the drug Clemastine target? | The drug Clemastine targets the gene HRH1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%clemastine%" OR LOWER(tradeNames_string) LIKE "%clemastine%" OR LOWER(drugSynonyms_string) LIKE "%clemastine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1580', 'drugName': 'Clemastine Fumarate', 'tradeNames_string': 'Clemastine fumarate, Tavegil, Tavist, Tavist-1', 'drugSynonyms_string': 'Clemastine fumarate, Clemastine hydrogen fumarate', 'linkedDiseasesDrug_string': 'Common Cold (EFO_0007214), Multiple Sclerosis (MONDO_0005301), Seasonal Allergic Rhinitis (EFO_0003956), Chronic Progressive Multiple Sclerosis (EFO_0003840), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_6183', 'drugName': 'Clemastine', 'tradeNames_string': '', 'drugSynonyms_string': 'Clemastin, Clemastine, HS-592, NSC-756685', 'linkedDiseasesDrug_string': 'Optic Neuritis (EFO_0007405), Common Cold (EFO_0007214), Multiple Sclerosis (MONDO_0005301), Seasonal Allergic Rhinitis (EFO_0003956), Chronic Progressive Multiple Sclerosis (EFO_0003840), Angioedema (EFO_0005532), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Allergic Rhinitis (EFO_0005854), Allergic Disease (MONDO_0005271), Urticaria (EFO_0005531), Pruritus (HP_0000989), Dermatitis (MONDO_0002406)', 'yearOfFirstApproval': 1977, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH1 (ENSG00000196639)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1469 | Q17 | What gene does the drug Thiamylal Sodium target? | The drug Thiamylal Sodium targets 16 genes: GABRG2, GABRE, GABRA4, GABRQ, GABRD, GABRA3, GABRP, GABRA5, GABRG3, GABRB2, GABRB3, GABRG1, GABRA2, GABRB1, GABRA6 and GABRA1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%thiamylal sodium%" OR LOWER(tradeNames_string) LIKE "%thiamylal sodium%" OR LOWER(drugSynonyms_string) LIKE "%thiamylal sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3421', 'drugName': 'Thiamylal Sodium', 'tradeNames_string': 'Surital', 'drugSynonyms_string': 'NSC-759558, Sodium thiamylal, Thiamylal sodium, Thiamylal sodium salt', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1982, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABRA1 (ENSG00000022355), GABRB2 (ENSG00000145864), GABRG2 (ENSG00000113327), GABRB3 (ENSG00000166206), GABRA4 (ENSG00000109158), GABRG3 (ENSG00000182256), GABRQ (ENSG00000268089), GABRA3 (ENSG00000011677), GABRP (ENSG00000094755), GABRD (ENSG00000187730), GABRG1 (ENSG00000163285), GABRB1 (ENSG00000163288), GABRE (ENSG00000102287), GABRA2 (ENSG00000151834), GABRA5 (ENSG00000186297), GABRA6 (ENSG00000145863)', 'numberLinkedTargets': 16}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1984 | Q17 | What gene does the drug Thyrotropin Alfa target? | The drug Thyrotropin Alfa targets the gene TSHR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%thyrotropin alfa%" OR LOWER(tradeNames_string) LIKE "%thyrotropin alfa%" OR LOWER(drugSynonyms_string) LIKE "%thyrotropin alfa%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2659', 'drugName': 'Thyrotropin Alfa', 'tradeNames_string': 'Thyrogen', 'drugSynonyms_string': 'GX-30, Thyrotropin alfa, Thyrotropin alpha', 'linkedDiseasesDrug_string': 'Thyroid Neoplasm (EFO_0003841), Nodular Goiter (EFO_1001062), Thyroid Carcinoma (EFO_0002892), Graves Disease (EFO_0004237), Thyroid Cancer (MONDO_0002108)', 'yearOfFirstApproval': 1998, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TSHR (ENSG00000165409)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.527 | Q17 | What gene does the drug Aldesleukin target? | The drug Aldesleukin targets 3 genes: IL2RA, IL2RB and IL2RG. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%aldesleukin%" OR LOWER(tradeNames_string) LIKE "%aldesleukin%" OR LOWER(drugSynonyms_string) LIKE "%aldesleukin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5264', 'drugName': 'Aldesleukin', 'tradeNames_string': 'Proleukin', 'drugSynonyms_string': 'Aldesleukin, Human interleukin-2, Human interleukin-2 125-serine, ILT-101, Ilt-101, Ilt-101 (low dose il-2), Interleukin 2, Interleukin-2, Interleukin-2 aldesleukin, Interleukin-2(2-133),125-ser, Recombinant interleukin-2 human', 'linkedDiseasesDrug_string': "Ovarian Carcinoma (EFO_0001075), Multiple Myeloma (EFO_0001378), Skin Cancer (MONDO_0002898), Behcet'S Syndrome (EFO_0003780), Refractory Anemia (EFO_0003802), Acute Myelomonocytic Leukemia (EFO_0000223), Pemphigus Vulgaris (EFO_0004719), Acute Myeloblastic Leukemia Without Maturation (EFO_0003027), Acute Basophilic Leukemia (EFO_0003029), Inflammatory Breast Carcinoma (EFO_1000984), Myelodysplastic/Myeloproliferative Disease (MONDO_0020077), Alopecia Areata (EFO_0004192), Clear Cell Renal Carcinoma (EFO_0000349), Wiskott-Aldrich Syndrome (MONDO_0010518), Habitual Abortion (EFO_1000954), Hiv-1 Infection (EFO_0000180), Myositis (EFO_0000783), Carcinoma (EFO_0000313), Acute Erythroleukemia (EFO_0000218), Liver Cancer (MONDO_0002691), Follicular Lymphoma (MONDO_0018906), Lung Cancer (MONDO_0008903), Leukemia (EFO_0000565), Leiomyosarcoma (EFO_0000564), Sezary'S Disease (EFO_1000785), Cancer (MONDO_0004992), Non-Hodgkins Lymphoma (EFO_0005952), Chronic Lymphocytic Leukemia (EFO_0000095), Encephalitis (MONDO_0019956), Myelodysplastic Syndrome (EFO_0000198), Colorectal Carcinoma (EFO_1001951), Urticaria (EFO_0005531), Cryoglobulinemia (EFO_0005846), Hepatocellular Carcinoma (EFO_0000182), Fallopian Tube Carcinoma (EFO_1000251), Gliosarcoma (EFO_1001465), Acute Lymphoblastic Leukemia (EFO_0000220), Acute Myeloid Leukemia (EFO_0000222), Polymyalgia Rheumatica (EFO_0008518), Diffuse Large B-Cell Lymphoma (EFO_0000403), Dermatomyositis (EFO_0000398), Metastasis (EFO_0009708), Allergic Conjunctivitis (EFO_0007141), Anemia, Hemolytic, Autoimmune (EFO_1001264), Thyroid Cancer (MONDO_0002108), Hodgkins Lymphoma (EFO_0000183), Metastatic Neoplasm (EFO_0009709), Merkel Cell Skin Cancer (EFO_1001471), Hiv Infection (EFO_0000764), Myeloproliferative Disorder (EFO_0004251), Non-Small Cell Lung Carcinoma (EFO_0003060), Acute Monocytic Leukemia (EFO_0000221), Neuroblastoma (EFO_0000621), Alzheimer Disease (MONDO_0004975), Coronary Artery Disease (EFO_0001645), Macrophage Activation Syndrome (EFO_1001806), Hematopoietic And Lymphoid Cell Neoplasm (MONDO_0044881), Urothelial Carcinoma (EFO_0008528), Aids (EFO_0000765), Blast Phase Chronic Myelogenous Leukemia, Bcr-Abl1 Positive (EFO_1000131), Ovarian Cancer (MONDO_0008170), Breast Neoplasm (EFO_0003869), Breast Cancer (MONDO_0007254), Lymphoma (EFO_0000574), Acute Coronary Syndrome (EFO_0005672), Mycosis Fungoides (EFO_1001051), Acute Megakaryoblastic Leukaemia (EFO_0003025), Central Nervous System Neoplasm (EFO_1000158), Abnormality Of Blood And Blood-Forming Tissues (HP_0001871), Neoplasm Of Mature B-Cells (EFO_0000096), Mesothelioma (EFO_0000588), Peritoneum Cancer (MONDO_0002087), Cutaneous Melanoma (EFO_0000389), Chronic Myeloproliferative Disorder (EFO_0002428), Neoplasm (EFO_0000616), Urinary Bladder Cancer (MONDO_0001187), Sarcoma (EFO_0000691), Cytomegalovirus Infection (EFO_0001062), Synovial Sarcoma (EFO_0001376), Type 1 Diabetes Mellitus (MONDO_0005147), Graft Versus Host Disease (MONDO_0013730), Covid-19 (MONDO_0100096), Metastatic Melanoma (EFO_0002617), Systemic Lupus Erythematosus (MONDO_0007915), Burkitts Lymphoma (EFO_0000309), Ulcerative Colitis (EFO_0000729), Chronic Myelogenous Leukemia (EFO_0000339), Prostate Adenocarcinoma (EFO_0000673), Hepatitis C Virus Infection (EFO_0003047), Nephrotic Syndrome (EFO_0004255), Prostate Cancer (MONDO_0008315), Crohn'S Disease (EFO_0000384), Male Breast Carcinoma (EFO_0006861), Chronic Myelomonocytic Leukemia (EFO_1001779), Cervical Carcinoma (EFO_0001061), Acute Graft Vs. Host Disease (EFO_0004599), Relapsing Polychondritis (EFO_1001148), Refractory Anemia With Excess Blasts (EFO_0003811), Human Papilloma Virus Infection (EFO_0001668), Renal Cell Carcinoma (EFO_0000681), Kidney Neoplasm (EFO_0003865), Ovarian Neoplasm (EFO_0003893), Head And Neck Malignant Neoplasia (EFO_0006859), Fallopian Tube Cancer (MONDO_0002158), Amyotrophic Lateral Sclerosis (MONDO_0004976), Kidney Cancer (MONDO_0002367), Melanoma (EFO_0000756), Squamous Cell Intraepithelial Neoplasia (MONDO_0024475), Esophageal Cancer (MONDO_0007576)", 'yearOfFirstApproval': 1992, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL2RA (ENSG00000134460), IL2RG (ENSG00000147168), IL2RB (ENSG00000100385)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.23 | Q17 | What gene does the drug Ipragliflozin target? | The drug Ipragliflozin is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene SLC5A2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ipragliflozin%" OR LOWER(tradeNames_string) LIKE "%ipragliflozin%" OR LOWER(drugSynonyms_string) LIKE "%ipragliflozin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2703', 'drugName': 'Ipragliflozin', 'tradeNames_string': '', 'drugSynonyms_string': 'ASP-1941, Ipragliflozin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2404', 'drugName': 'Ipragliflozin L-Proline', 'tradeNames_string': '', 'drugSynonyms_string': 'Ipragliflozin l-proline', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'SLC5A2 (ENSG00000140675)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.361 | Q17 | What gene does the drug Osilodrostat target? | The drug Osilodrostat targets the gene CYP11B1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%osilodrostat%" OR LOWER(tradeNames_string) LIKE "%osilodrostat%" OR LOWER(drugSynonyms_string) LIKE "%osilodrostat%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5691', 'drugName': 'Osilodrostat', 'tradeNames_string': '', 'drugSynonyms_string': 'LCI-699-NX, LCI699-NX, Lci-699, Lci699, Osilodrostat', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110), Cushing Syndrome (EFO_0003099), Liver Disease (EFO_0001421), Hypertension (EFO_0000537), Adrenal Gland Disease (EFO_0005539), Kidney Disease (EFO_0003086), Essential Hypertension (MONDO_0001134), Primary Hyperaldosteronism (HP_0011736)", 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_5216', 'drugName': 'Osilodrostat Phosphate', 'tradeNames_string': 'Isturisa', 'drugSynonyms_string': 'LCI699-AZA, Osilodrostat phosphate', 'linkedDiseasesDrug_string': "Pituitary-Dependent Cushing'S Disease (EFO_1001110)", 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CYP11B1 (ENSG00000160882)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1288 | Q17 | What gene does the drug Ixekizumab target? | The drug Ixekizumab targets the gene IL17A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%ixekizumab%" OR LOWER(tradeNames_string) LIKE "%ixekizumab%" OR LOWER(drugSynonyms_string) LIKE "%ixekizumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3578', 'drugName': 'Ixekizumab', 'tradeNames_string': 'Taltz', 'drugSynonyms_string': 'Ixekizumab, LY-2439821, LY2439821', 'linkedDiseasesDrug_string': 'Psoriasis (EFO_0000676), Stricture (EFO_0006818), Pyoderma (HP_0000999), Ankylosing Spondylitis (EFO_0003898), Covid-19 (MONDO_0100096), Psoriatic Arthritis (EFO_0003778), Bullous Pemphigoid (EFO_0007187), Rheumatoid Arthritis (EFO_0000685), Major Depressive Disorder (MONDO_0002009), Pityriasis Rubra Pilaris (MONDO_0100017), Type 1 Diabetes Mellitus (MONDO_0005147), Immune System Disease (EFO_0000540), Lichen Planopilaris (EFO_0009856), Psoriasis Vulgaris (EFO_1001494)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'IL17A (ENSG00000112115)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1326 | Q17 | What gene does the drug Magnesium Oxybate target? | The drug Magnesium Oxybate targets 2 genes: GABBR2 and GABBR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%magnesium oxybate%" OR LOWER(tradeNames_string) LIKE "%magnesium oxybate%" OR LOWER(drugSynonyms_string) LIKE "%magnesium oxybate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2016', 'drugName': 'Magnesium Oxybate', 'tradeNames_string': '', 'drugSynonyms_string': 'Magnesium oxybate, Oxybate magnesium', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2020, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'GABBR1 (ENSG00000204681), GABBR2 (ENSG00000136928)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1683 | Q17 | What gene does the drug Osimertinib target? | The drug Osimertinib targets the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%osimertinib%" OR LOWER(tradeNames_string) LIKE "%osimertinib%" OR LOWER(drugSynonyms_string) LIKE "%osimertinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5692', 'drugName': 'Osimertinib', 'tradeNames_string': 'Tagrisso', 'drugSynonyms_string': 'AZD-9291, AZD-9291 FREE BASE, AZD9291, Azd-9291, Mereletinib, Osimertinib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Lung Adenocarcinoma (EFO_0000571), Squamous Cell Carcinoma (EFO_0000707), Lung Cancer (MONDO_0008903), Colorectal Cancer (MONDO_0005575), Adenocarcinoma (EFO_0000228), Neoplasm (EFO_0000616), Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Neoplasm (MONDO_0021117), Brain Neoplasm (EFO_0003833), Glioblastoma Multiforme (EFO_0000519), Carcinoma (EFO_0000313)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_649', 'drugName': 'Osimertinib Mesylate', 'tradeNames_string': 'Tagrisso', 'drugSynonyms_string': 'AZD-9291 MESYLATE, AZD9291 mesylate, Mereletinib mesilate, Mereletinib mesylate, Osimertinib mesilate, Osimertinib mesylate', 'linkedDiseasesDrug_string': 'Non-Small Cell Lung Carcinoma (EFO_0003060), Lung Cancer (MONDO_0008903)', 'yearOfFirstApproval': 2015, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.344 | Q17 | What gene does the drug Triamterene target? | The drug Triamterene targets 3 genes: SCNN1B, SCNN1A and SCNN1G. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%triamterene%" OR LOWER(tradeNames_string) LIKE "%triamterene%" OR LOWER(drugSynonyms_string) LIKE "%triamterene%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4230', 'drugName': 'Triamterene', 'tradeNames_string': 'Dyrenium, Dytac', 'drugSynonyms_string': 'NSC-639359, NSC-77625, SK&F 8542, SK&F-8542, SK-8542, Triamterene', 'linkedDiseasesDrug_string': 'Nephrotic Syndrome (EFO_0004255), Edema (EFO_0009373), Congestive Heart Failure (EFO_0000373), Preeclampsia (EFO_0000668), Coronary Artery Disease (EFO_0001645), Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Hypercholesterolemia (HP_0003124), Sudden Cardiac Arrest (EFO_0004278), Hyperaldosteronism (EFO_0009452), Type 2 Diabetes Mellitus (MONDO_0005148), Atherosclerosis (EFO_0003914), Cirrhosis Of Liver (EFO_0001422)', 'yearOfFirstApproval': 1964, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCNN1A (ENSG00000111319), SCNN1B (ENSG00000168447), SCNN1G (ENSG00000166828)', 'numberLinkedTargets': 3}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.437 | Q17 | What gene does the drug Tositumomab target? | The drug Tositumomab targets the gene MS4A1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%tositumomab%" OR LOWER(tradeNames_string) LIKE "%tositumomab%" OR LOWER(drugSynonyms_string) LIKE "%tositumomab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5886', 'drugName': 'Tositumomab', 'tradeNames_string': 'Bexxar', 'drugSynonyms_string': 'Tositumomab', 'linkedDiseasesDrug_string': 'Follicular Lymphoma (MONDO_0018906), Non-Hodgkins Lymphoma (EFO_0005952), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm Of Mature B-Cells (EFO_0000096), Lymphoma (EFO_0000574)', 'yearOfFirstApproval': 2003, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_2569', 'drugName': 'Tositumomab 131I', 'tradeNames_string': 'Bexxar', 'drugSynonyms_string': 'Tositumomab (131I), Tositumomab 131i, Tositumomab/iodine (131i) tositumomab', 'linkedDiseasesDrug_string': 'Multiple Myeloma (EFO_0001378), Non-Hodgkins Lymphoma (EFO_0005952), Follicular Lymphoma (MONDO_0018906), Mantle Cell Lymphoma (EFO_1001469), Chronic Lymphocytic Leukemia (EFO_0000095), Neoplasm Of Mature B-Cells (EFO_0000096), Lymphoblastic Lymphoma (MONDO_0000873), Lymphoma (EFO_0000574), Anaplastic Large Cell Lymphoma (EFO_0003032), Waldenstrom Macroglobulinemia (EFO_0009441), Burkitts Lymphoma (EFO_0000309), Diffuse Large B-Cell Lymphoma (EFO_0000403), Malt Lymphoma (EFO_0000191), Hodgkins Lymphoma (EFO_0000183)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'MS4A1 (ENSG00000156738)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.479 | Q17 | What gene does the drug Nabilone target? | The drug Nabilone targets the gene CNR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%nabilone%" OR LOWER(tradeNames_string) LIKE "%nabilone%" OR LOWER(drugSynonyms_string) LIKE "%nabilone%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2707', 'drugName': 'Nabilone', 'tradeNames_string': 'Cesamet', 'drugSynonyms_string': 'CPD 109514, CPD-109514, Nabilone', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Nausea (HP_0002018), Obsessive-Compulsive Disorder (EFO_0004242), Diabetic Neuropathy (EFO_1000783), Nausea And Vomiting (HP_0002017), Obesity (EFO_0001073), Neuropathic Pain (EFO_0005762), Fibromyalgia (EFO_0005687), Spasticity (HP_0001257), Cannabis Dependence (EFO_0007191), Post Operative Nausea And Vomiting (EFO_0004888), Parkinson Disease (MONDO_0005180), Suicidal Ideation (EFO_0004320)', 'yearOfFirstApproval': 1985, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CNR1 (ENSG00000118432)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.220 | Q17 | What gene does the drug Amifampridine Phosphate target? | The drug Amifampridine Phosphate targets 40 genes: KCNB1, KCND2, KCNA7, KCNG3, KCNA4, KCNQ1, KCNQ3, KCNA1, KCNC4, KCNS1, KCNG2, KCNA6, KCNV2, KCNA5, KCNH2, KCNS3, KCNQ4, KCND3, KCNG1, KCNB2, KCNH6, KCNC3, KCNG4, KCNF1, KCNH8, KCNS2, KCNA3, KCNQ2, KCNH4, KCNA10, KCNC2, KCNC1, KCNH1, KCNH3, KCNV1, KCNQ5, KCND1, KCNA2, KCNH7 and KCNH5. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%amifampridine phosphate%" OR LOWER(tradeNames_string) LIKE "%amifampridine phosphate%" OR LOWER(drugSynonyms_string) LIKE "%amifampridine phosphate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3435', 'drugName': 'Amifampridine Phosphate', 'tradeNames_string': 'Firdapse', 'drugSynonyms_string': '3,4-DAPP, Amifampridine phosphate, DAPP, Zenas', 'linkedDiseasesDrug_string': 'Myasthenia Gravis (EFO_0004991), Brugada Syndrome (MONDO_0015263), Spinal Muscular Atrophy (EFO_0008525), Muscle Atrophy (EFO_0009851)', 'yearOfFirstApproval': 2018, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'KCNQ1 (ENSG00000053918), KCND3 (ENSG00000171385), KCNH2 (ENSG00000055118), KCNA2 (ENSG00000177301), KCNA1 (ENSG00000111262), KCNQ2 (ENSG00000075043), KCNQ3 (ENSG00000184156), KCNA7 (ENSG00000104848), KCNQ5 (ENSG00000185760), KCNQ4 (ENSG00000117013), KCNH1 (ENSG00000143473), KCNA4 (ENSG00000182255), KCNA5 (ENSG00000130037), KCNA3 (ENSG00000177272), KCNA6 (ENSG00000151079), KCNC1 (ENSG00000129159), KCND2 (ENSG00000184408), KCNB2 (ENSG00000182674), KCNC4 (ENSG00000116396), KCNC3 (ENSG00000131398), KCNB1 (ENSG00000158445), KCNA10 (ENSG00000143105), KCNV1 (ENSG00000164794), KCNH5 (ENSG00000140015), KCNG3 (ENSG00000171126), KCNG4 (ENSG00000168418), KCNV2 (ENSG00000168263), KCNS1 (ENSG00000124134), KCNH8 (ENSG00000183960), KCNC2 (ENSG00000166006), KCNS3 (ENSG00000170745), KCNH6 (ENSG00000173826), KCNF1 (ENSG00000162975), KCNH7 (ENSG00000184611), KCND1 (ENSG00000102057), KCNG1 (ENSG00000026559), KCNG2 (ENSG00000178342), KCNH3 (ENSG00000135519), KCNS2 (ENSG00000156486), KCNH4 (ENSG00000089558)', 'numberLinkedTargets': 40}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.919 | Q17 | What gene does the drug Emd-1201081 target? | The drug Emd-1201081 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TLR9. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%emd-1201081%" OR LOWER(tradeNames_string) LIKE "%emd-1201081%" OR LOWER(drugSynonyms_string) LIKE "%emd-1201081%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2813', 'drugName': 'Emd-1201081', 'tradeNames_string': '', 'drugSynonyms_string': 'Emd-1201081, HYB-2055, IMO-2055, Imo-2055, Imoxine', 'linkedDiseasesDrug_string': 'Renal Cell Carcinoma (EFO_0000681), Colorectal Carcinoma (EFO_1001951), Non-Small Cell Lung Carcinoma (EFO_0003060)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'TLR9 (ENSG00000239732)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1237 | Q17 | What gene does the drug Pentazocine target? | The drug Pentazocine targets the gene SIGMAR1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pentazocine%" OR LOWER(tradeNames_string) LIKE "%pentazocine%" OR LOWER(drugSynonyms_string) LIKE "%pentazocine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1542', 'drugName': 'Pentazocine', 'tradeNames_string': 'Fortral, Talwin', 'drugSynonyms_string': 'Dl-pentazocine, NIH-7958, NSC-107430, Pentazocine, Pentazocine civ, WIN 20,228, WIN-20228', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843), Bipolar Disorder (MONDO_0004985)', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SIGMAR1 (ENSG00000147955)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_652', 'drugName': 'Pentazocine Lactate', 'tradeNames_string': 'Talwin', 'drugSynonyms_string': 'Pentazocine lactate, Talwin (lactate)', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1967, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SIGMAR1 (ENSG00000147955)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_3200', 'drugName': 'Pentazocine Hydrochloride', 'tradeNames_string': 'Sosegon, Talwin, Talwin 50', 'drugSynonyms_string': 'Pentazocine hcl, Pentazocine hydrochloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1969, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SIGMAR1 (ENSG00000147955)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1597 | Q17 | What gene does the drug Asp-8374 target? | The drug Asp-8374 is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene TIGIT. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%asp-8374%" OR LOWER(tradeNames_string) LIKE "%asp-8374%" OR LOWER(drugSynonyms_string) LIKE "%asp-8374%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4338', 'drugName': 'Asp-8374', 'tradeNames_string': '', 'drugSynonyms_string': 'ASP-8374, ASP8374, Asp 8374, Asp-8374, Asp8374, PTZ-201', 'linkedDiseasesDrug_string': 'Neoplasm (EFO_0000616), Glioblastoma Multiforme (EFO_0000519)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'TIGIT (ENSG00000181847)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1020 | Q17 | What gene does the drug Trilaciclib Dihydrochloride target? | The drug Trilaciclib Dihydrochloride targets 2 genes: CDK4 and CDK6. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%trilaciclib dihydrochloride%" OR LOWER(tradeNames_string) LIKE "%trilaciclib dihydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%trilaciclib dihydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3859', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_string': 'Cosela', 'drugSynonyms_string': 'Trilaciclib dihydrochloride', 'linkedDiseasesDrug_string': 'Small Cell Lung Carcinoma (EFO_0000702)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_3860', 'drugName': 'Trilaciclib Dihydrochloride', 'tradeNames_string': 'Cosela', 'drugSynonyms_string': 'Trilaciclib dihydrochloride', 'linkedDiseasesDrug_string': 'Small Cell Lung Carcinoma (EFO_0000702)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CDK6 (ENSG00000105810), CDK4 (ENSG00000135446)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1950 | Q17 | What gene does the drug Theliatinib target? | The drug Theliatinib is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene EGFR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%theliatinib%" OR LOWER(tradeNames_string) LIKE "%theliatinib%" OR LOWER(drugSynonyms_string) LIKE "%theliatinib%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1898', 'drugName': 'Theliatinib', 'tradeNames_string': '', 'drugSynonyms_string': 'HMPL-309, Hmpl-309, Theliatinib, Xiliertinib', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 1, 'drugIsApproved': False, 'newLinkedTargets_string': 'EGFR (ENSG00000146648)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.96 | Q17 | What gene does the drug Robalzotan target? | The drug Robalzotan is not approved by the FDA. However, it is currently undergoing clinical trials and indicated to target the gene HTR1A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%robalzotan%" OR LOWER(tradeNames_string) LIKE "%robalzotan%" OR LOWER(drugSynonyms_string) LIKE "%robalzotan%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_84', 'drugName': 'Robalzotan', 'tradeNames_string': '', 'drugSynonyms_string': 'Azd-7371, NAD-299, Robalzotan', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 2, 'drugIsApproved': False, 'newLinkedTargets_string': 'HTR1A (ENSG00000178394)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1017 | Q17 | What gene does the drug Cortivazol target? | The drug Cortivazol targets the gene NR3C1. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%cortivazol%" OR LOWER(tradeNames_string) LIKE "%cortivazol%" OR LOWER(drugSynonyms_string) LIKE "%cortivazol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2892', 'drugName': 'Cortivazol', 'tradeNames_string': 'Altim', 'drugSynonyms_string': 'Cortivazol, NSC-80998', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'NR3C1 (ENSG00000113580)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1079 | Q17 | What gene does the drug Epoprostenol Sodium target? | The drug Epoprostenol Sodium targets the gene PTGIR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%epoprostenol sodium%" OR LOWER(tradeNames_string) LIKE "%epoprostenol sodium%" OR LOWER(drugSynonyms_string) LIKE "%epoprostenol sodium%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1500', 'drugName': 'Epoprostenol Sodium', 'tradeNames_string': 'Epoprostenol sodium, Flolan, Veletri', 'drugSynonyms_string': 'Epoprostenol sodium, Epoprostenolsodium, Prostacyclin sodium salt, Sodium prostacyclin, U-53,217A, U-53217A', 'linkedDiseasesDrug_string': 'Pulmonary Arterial Hypertension (EFO_0001361)', 'yearOfFirstApproval': 1995, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PTGIR (ENSG00000160013)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1101 | Q17 | What gene does the drug Fosphenytoin target? | The drug Fosphenytoin targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fosphenytoin%" OR LOWER(tradeNames_string) LIKE "%fosphenytoin%" OR LOWER(drugSynonyms_string) LIKE "%fosphenytoin%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_993', 'drugName': 'Fosphenytoin', 'tradeNames_string': '', 'drugSynonyms_string': 'Fosphenytoin, Np-06', 'linkedDiseasesDrug_string': 'Status Epilepticus (EFO_0008526), Epilepsy (EFO_0000474), Seizure (HP_0001250)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}, {'UUID': 'DrugGeneTargets_v2_181', 'drugName': 'Fosphenytoin Sodium', 'tradeNames_string': 'Cerebyx, Fosphenytoin sodium, Pro-epanutin, Sesquient', 'drugSynonyms_string': 'ACC-9653-010, ACC-9653-010 (SODIUM SALT), CI 982, CI-982, Fosphenytoin disodium salt, Fosphenytoin sodium', 'linkedDiseasesDrug_string': 'Seizure (HP_0001250)', 'yearOfFirstApproval': 1996, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1586 | Q17 | What gene does the drug Olaratumab target? | The drug Olaratumab targets the gene PDGFRA. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%olaratumab%" OR LOWER(tradeNames_string) LIKE "%olaratumab%" OR LOWER(drugSynonyms_string) LIKE "%olaratumab%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_3645', 'drugName': 'Olaratumab', 'tradeNames_string': 'Lartruvo', 'drugSynonyms_string': 'IMC-3G3, IMC3G3, Olaratumab', 'linkedDiseasesDrug_string': 'Pancreatic Carcinoma (EFO_0002618), Prostate Cancer (MONDO_0008315), Neoplasm (EFO_0000616), Leiomyosarcoma (EFO_0000564), Non-Small Cell Lung Carcinoma (EFO_0003060), Sarcoma (EFO_0000691), Soft Tissue Sarcoma (EFO_1001968), Gastrointestinal Stromal Tumor (MONDO_0011719), Glioblastoma Multiforme (EFO_0000519), Metastasis (EFO_0009708), Ovarian Neoplasm (EFO_0003893)', 'yearOfFirstApproval': 2016, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'PDGFRA (ENSG00000134853)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1321 | Q17 | What gene does the drug Testosterone Propionate target? | The drug Testosterone Propionate targets the gene AR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%testosterone propionate%" OR LOWER(tradeNames_string) LIKE "%testosterone propionate%" OR LOWER(drugSynonyms_string) LIKE "%testosterone propionate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2128', 'drugName': 'Testosterone Propionate', 'tradeNames_string': 'Testosterone propionate', 'drugSynonyms_string': 'NRB-03689, NSC-9166, Orchisterone, Testosteron 17-propionate, Testosterone 17.beta.-propionate, Testosterone Propionate, Testosterone propionate, Testosterone propionate ciii, Testosteroni propionas, Virormone', 'linkedDiseasesDrug_string': 'Atrophic Vaginitis (EFO_1001271)', 'yearOfFirstApproval': 1974, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'AR (ENSG00000169083)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.703 | Q17 | What gene does the drug Mequinol target? | The drug Mequinol targets the gene TYR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mequinol%" OR LOWER(tradeNames_string) LIKE "%mequinol%" OR LOWER(drugSynonyms_string) LIKE "%mequinol%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_5010', 'drugName': 'Mequinol', 'tradeNames_string': '', 'drugSynonyms_string': '4-hydroxyanisole, 4-methoxyphenol, 4ha, BMS-181158, Hqmme; hydroxyquinone methyl ether, Leucobasal, Leucodine b, Mechinolum, Menthyl anthranilate, Mequinol, NSC-4960, Novo-dermoquinona, P-guaiacol, P-hydroxyanisole', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 1999, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'TYR (ENSG00000077498)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1794 | Q17 | What gene does the drug Methylphenidate target? | The drug Methylphenidate targets 2 genes: SLC6A2 and SLC6A3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%methylphenidate%" OR LOWER(tradeNames_string) LIKE "%methylphenidate%" OR LOWER(drugSynonyms_string) LIKE "%methylphenidate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2371', 'drugName': 'Methylphenidate', 'tradeNames_string': 'Concerta, Cotempla xr-odt, Daytrana', 'drugSynonyms_string': 'Concerta, Methylin, Methylphenidate, Methylphenidate extended release, Prc-063, Threo-dl-methylphenidate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Multiple Sclerosis (MONDO_0005301), Eating Disorder (EFO_0005203), Conduct Disorder (EFO_0004216), Prostate Carcinoma (EFO_0001663), Lymphoid Neoplasm (EFO_0001642), Post-Traumatic Stress Disorder (EFO_0001358), Prostate Cancer (MONDO_0008315), Nicotine Dependence (EFO_0003768), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Cocaine Dependence (EFO_0002610), Asthenia (EFO_0007625), Childhood Apraxia Of Speech (MONDO_0011184), Sleep Disorder (EFO_0008568), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Delirium (EFO_0009267), Chronic Progressive Multiple Sclerosis (EFO_0003840), Sickle Cell Anemia (MONDO_0011382), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Brain Neoplasm (EFO_0003833), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Bipolar Disorder (MONDO_0004985), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Post-Operative Sign Or Symptom (EFO_0005323), Chronic Pain (HP_0012532), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2116', 'drugName': 'Serdexmethylphenidate', 'tradeNames_string': '', 'drugSynonyms_string': 'Serdexmethylphenidate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2117', 'drugName': 'Serdexmethylphenidate', 'tradeNames_string': '', 'drugSynonyms_string': 'Serdexmethylphenidate', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4160', 'drugName': 'Serdexmethylphenidate Chloride', 'tradeNames_string': '', 'drugSynonyms_string': 'KP415 Cl, Serdexmethylphenidate chloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5957', 'drugName': 'Dexmethylphenidate Hydrochloride', 'tradeNames_string': 'Dexmethylphenidate hydrochloride, Focalin, Focalin xr', 'drugSynonyms_string': 'Dex-methylphenidate hydrochloride, Dexmethylphenidate hcl, Dexmethylphenidate hydrochloride, Methylphenidate d-threo-form hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_846', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugSynonyms_string': 'Aptensio, Aptensio xr, Foquest, Metadate, Methylphenidate HCl, Methylphenidate hcl, Methylphenidate hydrochloride, Methylphenidate hydrochloride cii, NSC-169868, Oros mph, Quillichew, Quillivant, SPD-544, SPD544', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5779', 'drugName': 'Dexmethylphenidate', 'tradeNames_string': '', 'drugSynonyms_string': 'Dexmethylphenidate, Methylphenidate d-threo-form', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5778', 'drugName': 'Dexmethylphenidate', 'tradeNames_string': '', 'drugSynonyms_string': 'Dexmethylphenidate, Methylphenidate d-threo-form', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_4161', 'drugName': 'Serdexmethylphenidate Chloride', 'tradeNames_string': '', 'drugSynonyms_string': 'KP415 Cl, Serdexmethylphenidate chloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5956', 'drugName': 'Dexmethylphenidate Hydrochloride', 'tradeNames_string': 'Dexmethylphenidate hydrochloride, Focalin, Focalin xr', 'drugSynonyms_string': 'Dex-methylphenidate hydrochloride, Dexmethylphenidate hcl, Dexmethylphenidate hydrochloride, Methylphenidate d-threo-form hydrochloride', 'linkedDiseasesDrug_string': 'Attention Deficit Hyperactivity Disorder (EFO_0003888)', 'yearOfFirstApproval': 2001, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A2 (ENSG00000103546), SLC6A3 (ENSG00000142319)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_2370', 'drugName': 'Methylphenidate', 'tradeNames_string': 'Concerta, Cotempla xr-odt, Daytrana', 'drugSynonyms_string': 'Concerta, Methylin, Methylphenidate, Methylphenidate extended release, Prc-063, Threo-dl-methylphenidate', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Alzheimer Disease (MONDO_0004975), Orthostatic Hypotension (EFO_0005252), Multiple Sclerosis (MONDO_0005301), Eating Disorder (EFO_0005203), Conduct Disorder (EFO_0004216), Prostate Carcinoma (EFO_0001663), Lymphoid Neoplasm (EFO_0001642), Post-Traumatic Stress Disorder (EFO_0001358), Prostate Cancer (MONDO_0008315), Nicotine Dependence (EFO_0003768), Dementia (HP_0000726), Parkinson Disease (MONDO_0005180), Attention Deficit Hyperactivity Disorder (EFO_0003888), Anxiety (EFO_0005230), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Cocaine Dependence (EFO_0002610), Asthenia (EFO_0007625), Childhood Apraxia Of Speech (MONDO_0011184), Sleep Disorder (EFO_0008568), Methamphetamine Dependence (EFO_0004701), Drug Dependence (EFO_0003890), Delirium (EFO_0009267), Chronic Progressive Multiple Sclerosis (EFO_0003840), Sickle Cell Anemia (MONDO_0011382), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Brain Neoplasm (EFO_0003833), Brain Injury (MONDO_0043510), Depressive Disorder (MONDO_0002050), Bipolar Disorder (MONDO_0004985), Alcohol Dependence (MONDO_0007079), Opioid Dependence (EFO_0005611), Post-Operative Sign Or Symptom (EFO_0005323), Chronic Pain (HP_0012532), Major Depressive Disorder (MONDO_0002009), Fatigue (HP_0012378), Schizophrenia (MONDO_0005090)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_845', 'drugName': 'Methylphenidate Hydrochloride', 'tradeNames_string': 'Adhansia xr, Aptensio xr, Concerta, Delmosart, Equasym, Equasym xl, Jornay pm, Matoride xl, Medikinet, Medikinet xl, Metadate cd, Metadate er, Methylin, Methylin er, Methylphenidate hydrochloride, Quillichew er, Quillivant xr, Relexxii, Ritalin, Ritalin la, Ritalin sr, Ritalin-sr, Tranquilyn, Xenidate xl', 'drugSynonyms_string': 'Aptensio, Aptensio xr, Foquest, Metadate, Methylphenidate HCl, Methylphenidate hcl, Methylphenidate hydrochloride, Methylphenidate hydrochloride cii, NSC-169868, Oros mph, Quillichew, Quillivant, SPD-544, SPD544', 'linkedDiseasesDrug_string': 'Cancer (MONDO_0004992), Sleep Disorder (EFO_0008568), Conduct Disorder (EFO_0004216), Nicotine Dependence (EFO_0003768), Chronic Progressive Multiple Sclerosis (EFO_0003840), Attention Deficit Hyperactivity Disorder (EFO_0003888), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Fatigue (HP_0012378), Depressive Disorder (MONDO_0002050), Schizophrenia (MONDO_0005090), Childhood Apraxia Of Speech (MONDO_0011184)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SLC6A3 (ENSG00000142319), SLC6A2 (ENSG00000103546)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1005 | Q17 | What gene does the drug Pramlintide target? | The drug Pramlintide targets 4 genes: RAMP3, RAMP1, RAMP2 and CALCR. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pramlintide%" OR LOWER(tradeNames_string) LIKE "%pramlintide%" OR LOWER(drugSynonyms_string) LIKE "%pramlintide%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_359', 'drugName': 'Pramlintide', 'tradeNames_string': '', 'drugSynonyms_string': 'AC-0137, AC-137, AC0137, AC137, Pramlintide, Tripro-amylin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948), RAMP1 (ENSG00000132329), RAMP2 (ENSG00000131477), RAMP3 (ENSG00000122679)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2395', 'drugName': 'Pramlintide Acetate', 'tradeNames_string': 'Symlin, Symlinpen', 'drugSynonyms_string': 'AC0-137, AC0137, Pramlintide acetate, Pramlintide acetate anhydrous, Pramlintide acetate hydrate, Tripro-amylin acetate, Tripro-amylin acetate hydrate', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948), RAMP1 (ENSG00000132329), RAMP2 (ENSG00000131477), RAMP3 (ENSG00000122679)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2394', 'drugName': 'Pramlintide Acetate', 'tradeNames_string': 'Symlin, Symlinpen', 'drugSynonyms_string': 'AC0-137, AC0137, Pramlintide acetate, Pramlintide acetate anhydrous, Pramlintide acetate hydrate, Tripro-amylin acetate, Tripro-amylin acetate hydrate', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948), RAMP1 (ENSG00000132329), RAMP2 (ENSG00000131477), RAMP3 (ENSG00000122679)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_357', 'drugName': 'Pramlintide', 'tradeNames_string': '', 'drugSynonyms_string': 'AC-0137, AC-137, AC0137, AC137, Pramlintide, Tripro-amylin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948), RAMP1 (ENSG00000132329), RAMP2 (ENSG00000131477), RAMP3 (ENSG00000122679)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_358', 'drugName': 'Pramlintide', 'tradeNames_string': '', 'drugSynonyms_string': 'AC-0137, AC-137, AC0137, AC137, Pramlintide, Tripro-amylin', 'linkedDiseasesDrug_string': 'Diabetes Mellitus (EFO_0000400), Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948), RAMP1 (ENSG00000132329), RAMP2 (ENSG00000131477), RAMP3 (ENSG00000122679)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_2396', 'drugName': 'Pramlintide Acetate', 'tradeNames_string': 'Symlin, Symlinpen', 'drugSynonyms_string': 'AC0-137, AC0137, Pramlintide acetate, Pramlintide acetate anhydrous, Pramlintide acetate hydrate, Tripro-amylin acetate, Tripro-amylin acetate hydrate', 'linkedDiseasesDrug_string': 'Type 2 Diabetes Mellitus (MONDO_0005148), Obesity (EFO_0001073), Type 1 Diabetes Mellitus (MONDO_0005147)', 'yearOfFirstApproval': 2005, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CALCR (ENSG00000004948), RAMP1 (ENSG00000132329), RAMP2 (ENSG00000131477), RAMP3 (ENSG00000122679)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.156 | Q17 | What gene does the drug Mecamylamine target? | The drug Mecamylamine targets 2 genes: CHRNB4 and CHRNA3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%mecamylamine%" OR LOWER(tradeNames_string) LIKE "%mecamylamine%" OR LOWER(drugSynonyms_string) LIKE "%mecamylamine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1272', 'drugName': 'Mecamylamine Hydrochloride', 'tradeNames_string': 'Inversine, Mecamylamine hydrochloride', 'drugSynonyms_string': 'Mecamylamine chloride, Mecamylamine hcl, Mecamylamine hydrochloride, NSC-757086', 'linkedDiseasesDrug_string': 'Depressive Disorder (MONDO_0002050)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_120', 'drugName': 'Mecamylamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Mecamylamine', 'linkedDiseasesDrug_string': 'Autism (EFO_0003758), Macular Degeneration (EFO_0009606), Nicotine Dependence (EFO_0003768), Hypertension (EFO_0000537), Major Depressive Disorder (MONDO_0002009), Depressive Disorder (MONDO_0002050), Aging (GO_0007568), Alcohol Dependence (MONDO_0007079), Age-Related Macular Degeneration (EFO_0001365), Mental Deterioration (HP_0001268)', 'yearOfFirstApproval': 1956, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CHRNB4 (ENSG00000117971), CHRNA3 (ENSG00000080644)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_5354', 'drugName': 'Dexmecamylamine', 'tradeNames_string': '', 'drugSynonyms_string': 'Dexmecamylamine, NIH-11008, TC-5214, Tc-5214', 'linkedDiseasesDrug_string': 'Drug Dependence (EFO_0003890), Overactive Bladder (EFO_1000781), Hypertension (EFO_0000537), Kidney Disease (EFO_0003086), Major Depressive Disorder (MONDO_0002009), Hyperhidrosis (HP_0000975)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 3, 'drugIsApproved': False, 'newLinkedTargets_string': 'CHRNB2 (ENSG00000160716), CHRNA4 (ENSG00000101204)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1108 | Q17 | What gene does the drug Pitolisant target? | The drug Pitolisant targets the gene HRH3. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%pitolisant%" OR LOWER(tradeNames_string) LIKE "%pitolisant%" OR LOWER(drugSynonyms_string) LIKE "%pitolisant%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_1748', 'drugName': 'Pitolisant', 'tradeNames_string': 'Wakix, Wakix, europe', 'drugSynonyms_string': 'BF-2.649, BF-2649, BF2.649, Bf2.649, HBS-101, Pitolisant, Tiprolisant', 'linkedDiseasesDrug_string': 'Idiopathic Hypersomnia (MONDO_0018044), Drug Dependence (EFO_0003890), Hypersomnia (EFO_0005246), Narcolepsy (MONDO_0021107), Kidney Disease (EFO_0003086), Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Parkinson Disease (MONDO_0005180), Prader-Willi Syndrome (MONDO_0008300), Schizophrenia (MONDO_0005090), Alcohol Dependence (MONDO_0007079)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH3 (ENSG00000101180)', 'numberLinkedTargets': 1}, {'UUID': 'DrugGeneTargets_v2_1676', 'drugName': 'Pitolisant Hydrochloride', 'tradeNames_string': 'Wakix', 'drugSynonyms_string': 'Ciproxidine, Pitolisant hydrochloride', 'linkedDiseasesDrug_string': 'Narcolepsy-Cataplexy Syndrome (MONDO_0016158), Hypersomnia (EFO_0005246)', 'yearOfFirstApproval': 2019, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'HRH3 (ENSG00000101180)', 'numberLinkedTargets': 1}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1719 | Q17 | What gene does the drug Fingolimod target? | The drug Fingolimod targets 5 genes: S1PR3, S1PR4, S1PR5, S1PR1 and S1PR2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%fingolimod%" OR LOWER(tradeNames_string) LIKE "%fingolimod%" OR LOWER(drugSynonyms_string) LIKE "%fingolimod%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_4817', 'drugName': 'Fingolimod', 'tradeNames_string': 'Gilenya', 'drugSynonyms_string': 'FTY-720, Fingolimod', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Uveitis (EFO_1001231), Optic Neuritis (EFO_0007405), Asthma (MONDO_0004979), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Glioblastoma Multiforme (EFO_0000519), Multiple Sclerosis (MONDO_0005301), Amyotrophic Lateral Sclerosis (MONDO_0004976), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Chronic Progressive Multiple Sclerosis (EFO_0003840), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Renal Insufficiency (HP_0000083), Rett Syndrome (MONDO_0010726), Schizophrenia (MONDO_0005090), Immune System Disease (EFO_0000540), Primary Progressive Multiple Sclerosis (EFO_0008520), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4816', 'drugName': 'Fingolimod', 'tradeNames_string': 'Gilenya', 'drugSynonyms_string': 'FTY-720, Fingolimod', 'linkedDiseasesDrug_string': 'Anaplastic Astrocytoma (EFO_0002499), Uveitis (EFO_1001231), Optic Neuritis (EFO_0007405), Asthma (MONDO_0004979), Chronic Inflammatory Demyelinating Polyradiculoneuropathy (EFO_1000868), Glioblastoma Multiforme (EFO_0000519), Multiple Sclerosis (MONDO_0005301), Amyotrophic Lateral Sclerosis (MONDO_0004976), Stroke (EFO_0000712), Covid-19 (MONDO_0100096), Chronic Progressive Multiple Sclerosis (EFO_0003840), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Renal Insufficiency (HP_0000083), Rett Syndrome (MONDO_0010726), Schizophrenia (MONDO_0005090), Immune System Disease (EFO_0000540), Primary Progressive Multiple Sclerosis (EFO_0008520), Breast Carcinoma (EFO_0000305)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_5906', 'drugName': 'Fingolimod Lauryl Sulfate', 'tradeNames_string': 'Tascenso odt', 'drugSynonyms_string': 'Fingolimod lauryl sulfate, Tascenso', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 2021, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 5}, {'UUID': 'DrugGeneTargets_v2_4765', 'drugName': 'Fingolimod Hydrochloride', 'tradeNames_string': 'Gilenya', 'drugSynonyms_string': 'FTY-720 HYDROCHLORIDE, FTY720, FTY720 HYDROCHLORIDE, Fingolimod, Fingolimod (as hydrochloride), Fingolimod hcl, Fingolimod hydrochlorid, Fingolimod hydrochloride, Gilenia', 'linkedDiseasesDrug_string': 'Multiple Sclerosis (MONDO_0005301), Relapsing-Remitting Multiple Sclerosis (EFO_0003929), Breast Carcinoma (EFO_0000305), Amyotrophic Lateral Sclerosis (MONDO_0004976)', 'yearOfFirstApproval': 2010, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'S1PR5 (ENSG00000180739), S1PR2 (ENSG00000267534), S1PR4 (ENSG00000125910), S1PR3 (ENSG00000213694), S1PR1 (ENSG00000170989)', 'numberLinkedTargets': 5}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.1998 | Q17 | What gene does the drug Lercanidipine target? | The drug Lercanidipine targets 4 genes: CACNA1C, CACNA1D, CACNA1S and CACNA1F. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%lercanidipine%" OR LOWER(tradeNames_string) LIKE "%lercanidipine%" OR LOWER(drugSynonyms_string) LIKE "%lercanidipine%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_909', 'drugName': 'Lercanidipine', 'tradeNames_string': '', 'drugSynonyms_string': 'Lercanidipine, Lercanil', 'linkedDiseasesDrug_string': 'Hypertension (EFO_0000537), Cardiovascular Disease (EFO_0000319), Essential Hypertension (MONDO_0001134)', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}, {'UUID': 'DrugGeneTargets_v2_4021', 'drugName': 'Lercanidipine Hydrochloride', 'tradeNames_string': 'Cardiovasc, Carmen, Corifeo, Lercadip, Lercan, Lercapin, Lercaton, Lerkamen, Lerzam, Renovia, Vasodip, Zandip, Zanicor, Zanidip', 'drugSynonyms_string': 'Lercanidipine hcl, Lercanidipine hydrochloride, REC-15/2375', 'linkedDiseasesDrug_string': '', 'yearOfFirstApproval': 0, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'CACNA1C (ENSG00000151067), CACNA1S (ENSG00000081248), CACNA1D (ENSG00000157388), CACNA1F (ENSG00000102001)', 'numberLinkedTargets': 4}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.796 | Q17 | What gene does the drug Chloroprocaine Hydrochloride target? | The drug Chloroprocaine Hydrochloride targets 10 genes: SCN1A, SCN9A, SCN7A, SCN8A, SCN11A, SCN10A, SCN2A, SCN5A, SCN4A and SCN3A. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%chloroprocaine hydrochloride%" OR LOWER(tradeNames_string) LIKE "%chloroprocaine hydrochloride%" OR LOWER(drugSynonyms_string) LIKE "%chloroprocaine hydrochloride%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_2193', 'drugName': 'Chloroprocaine Hydrochloride', 'tradeNames_string': 'Ampres, Chloroprocaine hydrochloride, Clorotekal, Nesacaine, Nesacaine-mpf', 'drugSynonyms_string': 'Chloroprocaine HCl, Chloroprocaine hcl, Chloroprocaine hydrochloride, Chlorprocaine chloride', 'linkedDiseasesDrug_string': 'Pain (EFO_0003843)', 'yearOfFirstApproval': 1955, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'SCN1A (ENSG00000144285), SCN5A (ENSG00000183873), SCN4A (ENSG00000007314), SCN7A (ENSG00000136546), SCN2A (ENSG00000136531), SCN9A (ENSG00000169432), SCN3A (ENSG00000153253), SCN11A (ENSG00000168356), SCN8A (ENSG00000196876), SCN10A (ENSG00000185313)', 'numberLinkedTargets': 10}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Q17.587 | Q17 | What gene does the drug Timolol Maleate target? | The drug Timolol Maleate targets 2 genes: ADRB1 and ADRB2. | SELECT DISTINCT UUID, drugName, tradeNames_string, drugSynonyms_string, linkedDiseasesDrug_string, yearOfFirstApproval, maxClinicalTrialPhase, drugIsApproved, newLinkedTargets_string, numberLinkedTargets
FROM `{project_id}.{dataset_name}.DrugGeneTargets_ComprehensiveAnnotations_updated`
WHERE (LOWER(drugName) LIKE "%timolol maleate%" OR LOWER(tradeNames_string) LIKE "%timolol maleate%" OR LOWER(drugSynonyms_string) LIKE "%timolol maleate%")
ORDER BY maxClinicalTrialPhase DESC
LIMIT 100 | [{'UUID': 'DrugGeneTargets_v2_760', 'drugName': 'Timolol Maleate', 'tradeNames_string': 'Blocadren, Istalol, Timolol maleate, Timoptic, Timoptic Xe, Timoptic in ocudose, Timoptic-xe', 'drugSynonyms_string': 'Aquanil, NSC-757351, Ophtamolol, Timolol (as maleate), Timolol hydrogen maleate salt, Timolol maleate, Timolol maleate, s-enantiomer, Timololi maleas, WP-934', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Hemangioma (EFO_1000635), Portal Hypertension (EFO_0000666), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Corneal Edema (EFO_1000879), Anterior Ischemic Optic Neuropathy (EFO_1000809)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}, {'UUID': 'DrugGeneTargets_v2_761', 'drugName': 'Timolol Maleate', 'tradeNames_string': 'Blocadren, Istalol, Timolol maleate, Timoptic, Timoptic Xe, Timoptic in ocudose, Timoptic-xe', 'drugSynonyms_string': 'Aquanil, NSC-757351, Ophtamolol, Timolol (as maleate), Timolol hydrogen maleate salt, Timolol maleate, Timolol maleate, s-enantiomer, Timololi maleas, WP-934', 'linkedDiseasesDrug_string': 'Open-Angle Glaucoma (EFO_0004190), Hemangioma (EFO_1000635), Portal Hypertension (EFO_0000666), Ocular Hypertension (EFO_1001069), Glaucoma (MONDO_0005041), Corneal Edema (EFO_1000879), Anterior Ischemic Optic Neuropathy (EFO_1000809)', 'yearOfFirstApproval': 1978, 'maxClinicalTrialPhase': 4, 'drugIsApproved': True, 'newLinkedTargets_string': 'ADRB2 (ENSG00000169252), ADRB1 (ENSG00000043591)', 'numberLinkedTargets': 2}] | general | Distinct, Similarity Search, Order By | Genetic Target, Approval Status |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.